1
|
Swakowska K, Olejniczak D, Staniszewska A. Quality of Life of Residents in Seniors' Homes in Poland and Germany. Healthcare (Basel) 2024; 12:829. [PMID: 38667592 PMCID: PMC11049979 DOI: 10.3390/healthcare12080829] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2024] [Revised: 04/10/2024] [Accepted: 04/11/2024] [Indexed: 04/28/2024] Open
Abstract
BACKGROUND Homes for the elderly and care facilities are not only a place of treatment, but also a place of permanent residence for older people. It is assumed that older adults' quality of life in the centres may not be sufficient for their long well-being. The purpose of this study was to determine the level of quality of life among nursing home residents in Poland and Germany and the impact of disability on functioning in their major life domains. MATERIAL AND METHODS This study was carried out using the WHOQOL-BREF questionnaire (abridged version) on 1000 people-500 residents of the centre in Poland and 500 residents in Germany. RESULTS The quality of life of Polish and German residents is at an average level and is closely related to their degree of independence. People with greater independence assessed their quality of life higher. CONCLUSION The degree of disability affects one's own health and the quality of life of the residents. Therefore, to improve older adults' quality of life, certain steps should be taken, including supporting them in maintaining their health and independence on a daily basis.
Collapse
Affiliation(s)
| | - Dominik Olejniczak
- Department of Public Health, Medical University of Warsaw, 02-091 Warszawa, Poland;
| | - Anna Staniszewska
- Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, 02-091 Warszawa, Poland;
| |
Collapse
|
2
|
Hodson D, Mistry H, Guzzetti S, Davies M, Staniszewska A, Farrington P, Cadogan E, Yates J, Aarons L, Ogungbenro K. Mixed effects modeling of radiotherapy in combination with immune checkpoint blockade or inhibitors of the DNA damage response pathway. CPT Pharmacometrics Syst Pharmacol 2023; 12:1640-1652. [PMID: 37722071 PMCID: PMC10681475 DOI: 10.1002/psp4.13026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2023] [Revised: 07/08/2023] [Accepted: 07/17/2023] [Indexed: 09/20/2023] Open
Abstract
Dosage optimization to maximize efficacy and minimize toxicity is a potential issue when administering radiotherapy (RT) in combination with immune checkpoint blockade (ICB) or inhibitors of the DNA Damage Response Pathway (DDRi) in the clinic. Preclinical models and mathematical modeling can help identify ideal dosage schedules to observe beneficial effects of a tri-therapy. The aim of this study is to describe a mathematical model to capture the impact of RT in combination with inhibitors of the DNA Damage Response Pathway or blockade of the immune checkpoint protein - programmed death ligand 1 (PD-L1). This model describes how RT mediated activation of antigen presenting cells can induce an increase in cytolytic T cells capable of targeting tumor cells, and how combination drugs can potentiate the immune response by inhibiting the rate of T cell exhaustion. The model was fitted using preclinical data, where MC38 tumors were treated in vivo with RT alone or in combination with anti-PD-L1 as well as with either olaparib or the ataxia telangiectasia mutated (ATM) inhibitor-AZD0156. The model successfully described the observed data and goodness-of-fit, using visual predictive checks also confirmed a successful internal model validation for each treatment modality. The results demonstrated that the anti-PD-L1 effect in combination with RT was maximal in vivo and any additional benefit of DDRi at the given dosage and schedule used was undetectable. Model fit results indicated AZD0156 to be a more potent DDRi than olaparib. Simulations of alternative doses indicated that reducing efficacy of anti-PD-L1 by 68% would potentially provide evidence for a benefit of ATM inhibition in combination with ICB and increase the relative efficacy of tri-therapy.
Collapse
Affiliation(s)
- David Hodson
- Division of Pharmacy and Optometry, Faculty of Biology, Medicine and HealthThe University of ManchesterManchesterUK
| | - Hitesh Mistry
- Division of Pharmacy and Optometry, Faculty of Biology, Medicine and HealthThe University of ManchesterManchesterUK
| | - Sofia Guzzetti
- DMPK, Research and Early Development, Oncology R&DAstraZenecaCambridgeUK
| | - Michael Davies
- DMPK, Research and Early Development, Neuroscience R&DAstraZenecaCambridgeUK
| | - Anna Staniszewska
- Bioscience, Research and Early Development, Oncology R&DAstraZenecaCambridgeUK
| | - Paul Farrington
- Bioscience, Research and Early Development, Oncology R&DAstraZenecaCambridgeUK
| | - Elaine Cadogan
- Bioscience, Research and Early Development, Oncology R&DAstraZenecaCambridgeUK
| | | | - Leon Aarons
- Division of Pharmacy and Optometry, Faculty of Biology, Medicine and HealthThe University of ManchesterManchesterUK
| | - Kayode Ogungbenro
- Division of Pharmacy and Optometry, Faculty of Biology, Medicine and HealthThe University of ManchesterManchesterUK
| |
Collapse
|
3
|
Swakowska K, Religioni U, Staniszewska A. Opinion of Polish Patients with Epilepsy on Generic Medications. Healthcare (Basel) 2023; 11:2717. [PMID: 37893791 PMCID: PMC10606757 DOI: 10.3390/healthcare11202717] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2023] [Revised: 10/04/2023] [Accepted: 10/10/2023] [Indexed: 10/29/2023] Open
Abstract
AIM The majority of medicines used in Poland are generic drugs and substitutions of the originals. The objective of this study was to obtain information on the current knowledge about generic medicines among Polish patients with epilepsy. MATERIAL AND METHODS The conducted study was based on a self-developed questionnaire. The questionnaire consisted of 26 questions, including the questions regarding the respondents' knowledge about generics, their previous experience, and the factors behind these choices. RESULTS Overall, 1220 questionnaires were analyzed. Among all patients, 66.4% reportedly had heard about generics. Of these, 61.5% of patients had used generic drugs in the past. A significant proportion of participants had never been recommended to switch to a generic medicine by their healthcare professional (23% physicians and 13.9% pharmacists). Statistically, relevant differences were observed regarding the respondents' kind and level of education, place of residence, and net income per household. CONCLUSIONS Significant gaps were identified in the knowledge and perceptions among patients regarding generic medicines, especially in relation to their efficacy and safety. Efforts must be directed towards increasing public awareness of generic medicines and there should also be a focus on educating patients about generic medicines.
Collapse
Affiliation(s)
| | - Urszula Religioni
- School of Public Health, Centre of Postgraduate Medical Education of Warsaw, 01-826 Warsaw, Poland;
| | - Anna Staniszewska
- Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, 02-097 Warsaw, Poland
| |
Collapse
|
4
|
Hodson D, Mistry H, Yates J, Farrington P, Staniszewska A, Guzzetti S, Davies M, Aarons L, Ogungbenro K. Radiation in Combination with Immune Checkpoint Blockade and DNA Damage Response Inhibitors in Mice: Dosage Optimization in MC38 Syngeneic Tumors via Modelling and Simulation. J Pharmacol Exp Ther 2023; 387:44-54. [PMID: 37348964 DOI: 10.1124/jpet.122.001572] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2022] [Revised: 05/23/2023] [Accepted: 06/09/2023] [Indexed: 06/24/2023] Open
Abstract
Clinical trials assessing the impact of radiotherapy (RT) in combination with DNA damage response pathway inhibitors (DDRis) and/or immune checkpoint blockade are currently ongoing. However, current methods for optimizing dosage and schedule are limited. A mathematical model was developed to capture the impacts of RT in combination with DDRi and/or anti-PD-L1 [immune checkpoint inhibitor (ICI)] on tumor immune interactions in the MC38 syngeneic tumor model. The model was fitted to datasets that assessed the impact of RT in combination with the DNA protein kinase inhibitor (DNAPKi) AZD7648. The model was further fitted to datasets from studies that were used to assess both RT/ICI combinations as well as RT/ICI combinations followed by concurrent administration of the poly ADP ribose polymerase inhibitor (PARPi) olaparib. Nonlinear mixed-effects modeling was performed followed by internal validation with visual predictive checks (VPC). Simulations of alternative dosage regimens and scheduling were performed to identify optimal candidate dosage regimens of RT/DNAPKi and RT/PARPi/ICI. Model fits and VPCs confirmed a successful internal validation for both datasets and demonstrated very small differences in the median, lower, and upper percentile values of tumor diameters between RT/ICI and RT/PARPi/ICI, which indicated that the triple combination of RT/PARPi/ICI at the given dosage and schedule does not provide additional benefit compared with ICI in combination with RT. Simulation of alternative dosage regimens indicated that lowering the dosage of ICI to between 2 and 4 mg/kg could induce similar benefits to the full dosage regimen, which could be of translational benefit. SIGNIFICANCE STATEMENT: This work provides a mixed-effects model framework to quantify the effects of combination radiotherapy/DNA damage response pathway inhibitors/immune checkpoint inhibitors in preclinical tumor models and identify optimal dosage regimens, which could be of translational benefit.
Collapse
Affiliation(s)
- David Hodson
- Division of Pharmacy and Optometry, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester, United Kingdom (D.H., H.M., L.A., K.O.); DMPK (S.G., J.Y.) and Biosciences (P.F., A.S.), Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom; and DMPK, Research and Early Development, Neuroscience R&D, AstraZeneca, Cambridge, United Kingdom (M.D.)
| | - Hitesh Mistry
- Division of Pharmacy and Optometry, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester, United Kingdom (D.H., H.M., L.A., K.O.); DMPK (S.G., J.Y.) and Biosciences (P.F., A.S.), Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom; and DMPK, Research and Early Development, Neuroscience R&D, AstraZeneca, Cambridge, United Kingdom (M.D.)
| | - James Yates
- Division of Pharmacy and Optometry, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester, United Kingdom (D.H., H.M., L.A., K.O.); DMPK (S.G., J.Y.) and Biosciences (P.F., A.S.), Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom; and DMPK, Research and Early Development, Neuroscience R&D, AstraZeneca, Cambridge, United Kingdom (M.D.)
| | - Paul Farrington
- Division of Pharmacy and Optometry, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester, United Kingdom (D.H., H.M., L.A., K.O.); DMPK (S.G., J.Y.) and Biosciences (P.F., A.S.), Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom; and DMPK, Research and Early Development, Neuroscience R&D, AstraZeneca, Cambridge, United Kingdom (M.D.)
| | - Anna Staniszewska
- Division of Pharmacy and Optometry, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester, United Kingdom (D.H., H.M., L.A., K.O.); DMPK (S.G., J.Y.) and Biosciences (P.F., A.S.), Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom; and DMPK, Research and Early Development, Neuroscience R&D, AstraZeneca, Cambridge, United Kingdom (M.D.)
| | - Sofia Guzzetti
- Division of Pharmacy and Optometry, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester, United Kingdom (D.H., H.M., L.A., K.O.); DMPK (S.G., J.Y.) and Biosciences (P.F., A.S.), Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom; and DMPK, Research and Early Development, Neuroscience R&D, AstraZeneca, Cambridge, United Kingdom (M.D.)
| | - Michael Davies
- Division of Pharmacy and Optometry, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester, United Kingdom (D.H., H.M., L.A., K.O.); DMPK (S.G., J.Y.) and Biosciences (P.F., A.S.), Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom; and DMPK, Research and Early Development, Neuroscience R&D, AstraZeneca, Cambridge, United Kingdom (M.D.)
| | - Leon Aarons
- Division of Pharmacy and Optometry, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester, United Kingdom (D.H., H.M., L.A., K.O.); DMPK (S.G., J.Y.) and Biosciences (P.F., A.S.), Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom; and DMPK, Research and Early Development, Neuroscience R&D, AstraZeneca, Cambridge, United Kingdom (M.D.)
| | - Kayode Ogungbenro
- Division of Pharmacy and Optometry, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester, United Kingdom (D.H., H.M., L.A., K.O.); DMPK (S.G., J.Y.) and Biosciences (P.F., A.S.), Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom; and DMPK, Research and Early Development, Neuroscience R&D, AstraZeneca, Cambridge, United Kingdom (M.D.)
| |
Collapse
|
5
|
Moorthy G, Voronova V, Pichardo C, Peskov K, Illuzzi G, Staniszewska A, Albertella M, Kimko H. Abstract 2794: A Quantitative Systems Pharmacology (QSP) model to characterize dose-dependent antitumor activity of AZD5305, PARP1 selective inhibitor, across multiple xenograft models. Cancer Res 2023. [DOI: 10.1158/1538-7445.am2023-2794] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/07/2023]
Abstract
Abstract
AZD5305 is a potent and selective PARP1 inhibitor and trapper which is hypothesized to improve therapeutic index over first generation nonselective PARP inhibitors. AZD5305 demonstrated significant and sustained antitumor activity in multiple BRCA1/2 mutant xenograft models. Here we present a mechanistic Quantitative Systems Pharmacology (QSP) model to analyze dose-dependent antitumor activity of AZD5305 (0.01-10 mg/kg) across a selection of xenograft models with different homologous recombination repair (HRR) status (Capan-1, DLD-1 BRCA2 KO, HBCx-9, HBCx-17, MDA-MB-436 and SUM149PT). A QSP model was developed based on a system of ordinary differential equations (ODEs) to address formation and repair of trapped PARP-DNA fragments and longitudinal changes in tumor size as a function of pharmacokinetic (PK) profiles in individual animals. Tumor growth data as well as intratumoral PARylation inhibition from xenograft models were utilized for model development and qualification. Model parameters characterizing intrinsic tumor growth and cancer cell sensitivity to accumulated DNA damage, were set to be different across xenograft models, to provide unbiased data reproduction. Sensitivity analyses were performed to identify model parameters which have the most impact on differential antitumor activity observed across various xenograft models. Maximal antitumor efficacy was seen at 0.1 to 1 mg/kg AZD5305, depending on the tumor model. Exposures at 1 mg/kg were similar to those causing peak PARP1 trapping in vitro. The QSP model adequately captures antitumor activity across different xenograft models. Simulations indicate antitumor activity of AZD5305 was driven mainly by differences in the HRR status-related model parameter (khrr). Xenograft models with HRR deficiency such as HBCx-17, DLD-1 BRCA2 KO and MDA-MB-436 (with a very low khrr) were the most sensitive to AZD5305 and treatment led to tumor regressions. In contrast, tumor models with partial sensitivity, such as HBCx-9, Capan-1, SUM149PT (with khrr up to 1000-fold higher than in the sensitive tumors), AZD5305 only achieved tumor growth inhibition. Dosing AZD5305 at 0.03 mg/kg daily was associated with tumor regression in HBCx-17 and MDA-MB-436 xenografts, whereas 1 mg/kg daily dosing was required to achieve tumor regression in the DLD-1 BRCA2 KO model, and maximal tumor growth inhibition in less sensitive models. Further biomarker analyses to assess functional HRR status (e.g. via RAD51 foci score) in these xenograft models is ongoing to validate model estimated khrr parameters. The calibrated model was used to predict antitumor activity of AZD5305 at clinically relevant exposures observed in the phase I clinical study PETRA. Model-based simulations indicated near maximal efficacy at clinical doses equivalent to 1 mg/kg AZD5305 exposure in xenograft models.
Citation Format: Ganesh Moorthy, Veronika Voronova, Cesar Pichardo, Kirill Peskov, Giuditta Illuzzi, Anna Staniszewska, Mark Albertella, Holly Kimko. A Quantitative Systems Pharmacology (QSP) model to characterize dose-dependent antitumor activity of AZD5305, PARP1 selective inhibitor, across multiple xenograft models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 2794.
Collapse
|
6
|
Pergol-Metko P, Staniszewska A, Metko S, Sienkiewicz Z, Czyzewski L. Compassion Fatigue and Perceived Social Support among Polish Nurses. Healthcare (Basel) 2023; 11:healthcare11050706. [PMID: 36900712 PMCID: PMC10001227 DOI: 10.3390/healthcare11050706] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2022] [Revised: 02/22/2023] [Accepted: 02/23/2023] [Indexed: 03/06/2023] Open
Abstract
BACKGROUND Social support has a vital role in preventing traumatic stress in nurses. Nurses are regularly exposed to contact with violence, suffering, and death. The situation worsened during the pandemic because they were also faced with the possibility of infection SARS-CoV-2 and death from COVID-19. Many nurses are faced with increased pressure, stress, and other adverse effects on their mental health. The study aimed to measure the relationship between compassion fatigue and perceived social support in polish nurses. METHODS The study was conducted on 862 professionally active nurses in Poland using the CAWI method (Computer-Assisted Web Interview). The professional Quality of Life scale (ProQOL) and the Multidimensional Scale of Perceived Social Support (MSPSS) were used for collecting the data. StatSoft, Inc. (2014) was used for data analysis. For comparisons between the groups: Mann-Whitney U test, ANOVA Kruskal-Wallis test, and multiple comparisons (post-hoc). The relationships between variables were tested using Spearman's rho, Tau Kendall, and the chi-square test. RESULTS The research showed the presence of compassion satisfaction, compassion fatigue, and burnout in the group of Polish hospital nurses. A higher level of perceived social support was associated with lower compassion fatigue (r = -0.35; p < 0.001). A higher level of social support was associated with higher job satisfaction (r = 0.40; p < 0.001). The study also found that a higher level of social support was associated with a lower risk of burnout (r = -0.41; p < 0.001). CONCLUSIONS Preventing compassion fatigue and burnout should be a priority for healthcare managers. Notably, an essential predictor of compassion fatigue is that Polish nurses often work overtime. It is necessary to pay more attention to the crucial role of social support in preventing compassion fatigue and burnout.
Collapse
Affiliation(s)
- Paulina Pergol-Metko
- Department of Development of Nursing and Social & Medical Sciences, Medical University of Warsaw, 02-091 Warsaw, Poland
- Correspondence:
| | - Anna Staniszewska
- Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, 02-091 Warsaw, Poland
| | | | - Zofia Sienkiewicz
- Department of Development of Nursing and Social & Medical Sciences, Medical University of Warsaw, 02-091 Warsaw, Poland
| | - Lukasz Czyzewski
- Department of Geriatric Nursing, Medical University of Warsaw, 02-091 Warsaw, Poland
| |
Collapse
|
7
|
Jamal K, Staniszewska A, Gordon J, Pilger D, Illuzzi G, Wilson J, Smith A, Gosselin E, McWilliams L, Wen S, McGrath F, Dowdell G, Kabbabe D, Griffin M, Davies B, Hamerlik P, Schou M, Pike A, Johannes J. DDDR-01. AZD9574 IS A NOVEL, BRAIN PENETRANT PARP-1 SELECTIVE INHIBITOR WITH ACTIVITY IN AN INTRACRANIAL XENOGRAFT MODEL OF TRIPLE NEGATIVE BREAST CARCINOMA WITH HOMOLOGOUS RECOMBINATION REPAIR DEFICIENCY. Neuro Oncol 2022. [DOI: 10.1093/neuonc/noac209.366] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Abstract
The Poly (ADP-ribose) polymerase (PARP) family has numerous essential functions in cellular processes such as transcription, chromatin remodelling, DNA damage response and repair as well as apoptosis. PARP inhibition blocks base excision repair and results in conversion of SSBs to DNA double-strand break (DSBs), the most deleterious form of DNA damage. DSBs can be repaired by homologous recombination repair (HRR) or non-homologous end joining (NHEJ). The physiological importance of HRR is underscored by the observation of genomic instability in HRR-deficient (HRD+) cells and, importantly, the association of cancer predisposition and developmental defects with mutations in HRR genes. PARP1 and PARP2 are required for SSB repair, while PARP1 is also involved in the repair of DNA double-strand breaks (DSBs) and replication fork damage. AZD9574 is a novel brain penetrant PARP1 inhibitor that acts by selectively inhibiting and trapping PARP1 at the sites of SSBs. While AZD9574 inhibited PARP1 enzymatic activity in all tested cell lines irrespective of the HRR status (IC50 range between 0.3 – 2 nM), colony formation assay in isogenic cell lines pairs confirmed higher potency and selectivity towards HRD+ models. In vivo, AZD9574 demonstrated dose-dependent efficacy in a BRCA1 mutant MDA-MB-436 subcutaneous xenograft model. Anti-tumour effects of AZD9574 were manifested by significant growth regressions that were durable after treatment withdrawal. An intracranial xenograft model of breast cancer brain metastases was developed to assess the efficacy of AZD9574 in the context of blood-brain barrier penetrance. Treatment of animals with established intracranial lesions showed sustained tumour growth suppression resulting in a significantly extended survival of tumour-bearing mice. Collectively, we believe that our data support the development of AZD9574 as a potential therapy for patients with HRD+ breast cancer whose disease has spread to the brain.This abstract was previously presented at AACR 2022 (Hamerlik et al, AACR 2022, Abs #3880)
Collapse
Affiliation(s)
| | | | | | | | | | | | - Aaron Smith
- AstraZeneca , Saffron Walden , United Kingdom
| | | | | | | | | | | | | | | | | | | | | | - Andy Pike
- AstraZeneca , Saffron Walden , United Kingdom
| | | |
Collapse
|
8
|
Olejniczak D, Mularczyk-Tomczewska P, Klimiuk K, Olearczyk A, Kielan A, Staniszewska A, Osowiecka K. Coping with Stress in Neoplastic Diseases. Int J Environ Res Public Health 2022; 19:9675. [PMID: 35955039 PMCID: PMC9367910 DOI: 10.3390/ijerph19159675] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 06/09/2022] [Revised: 07/04/2022] [Accepted: 08/04/2022] [Indexed: 06/15/2023]
Abstract
Introduction: Disease-related stress is a common phenomenon. It also occurs in neoplastic diseases. Since physical and mental health are interrelated, it is important to make sure that treatment covers these two areas. Therefore, it is essential to learn how patients with neoplastic diseases can cope with stress. Materials and Methods: The respondents are 306 patients suffering from neoplastic diseases, associated in patient advocacy groups. The method is the Brief-COPE (Coping Orientation to Problems Experienced) questionnaire. Results: The following stress management strategies were most commonly adopted by the patients: acceptance (median 2.25; 25−75% IQR 2.0−3.0), active coping (median 2.0; 25−75% IQR (interquartile range) 1.5−2.0), planning (median 2.0; 25−75% IQR 2.0−2.0), emotional support (median 2.0; 25−75% IQR 1.5−2.0), instrumental support (median 2.0; 25−75% IQR 2.0−2.0), self-distraction (median 2.0; 25−75% IQR 1.5−3.0), and venting (median 2.0; 25−75% IQR 1.5−3.0). A decision to adopt a particular stress management strategy by patients with neoplastic diseases was highly affected by demographic factors (p < 0.05), such as sex, education, age, place of residence and employment. Conclusions: Teaching stress management strategies should be a part of the education process among patients with neoplastic diseases. Before or in the course of treatment, an oncology patient should be educated on the prevention of mental health disorders. The ability to cope with stress is one of the key competences for the course of neoplastic diseases and it can affect the treatment process. Stress management in chronic diseases, including neoplastic diseases, should be approached not only at the level of an individual person but also at the level of the health system as a whole.
Collapse
Affiliation(s)
- Dominik Olejniczak
- Department of Public Health, Faculty of Health Science, Medical University of Warsaw, 02-091 Warszawa, Poland
| | | | - Krzysztof Klimiuk
- Faculty of Medicine, Medical University of Gdańsk, 80-210 Gdansk, Poland
| | - Agata Olearczyk
- Department of Public Health, Faculty of Health Science, Medical University of Warsaw, 02-091 Warszawa, Poland
| | - Aleksandra Kielan
- Department of Public Health, Faculty of Health Science, Medical University of Warsaw, 02-091 Warszawa, Poland
| | - Anna Staniszewska
- Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, 02-091 Warszawa, Poland
| | - Karolina Osowiecka
- Department of Psychology and Sociology of Health and Public Health, School of Public Health, University of Warmia and Mazury in Olsztyn, 10-719 Olsztyn, Poland
| |
Collapse
|
9
|
Wallez Y, Proia T, Leo E, Bradshaw L, Wilson Z, Owusu J, Cheraghchi-Bashi-Astaneh A, Staniszewska A, O’Connor M, Cosulich S, Mettetal J. Abstract 1142: Activity and tolerability of combination of trastuzumab deruxtecan with the next generation PARP1-selective inhibitor AZD5305 in preclinical models. Cancer Res 2022. [DOI: 10.1158/1538-7445.am2022-1142] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate composed of an anti-HER2 antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor, approved for HER2+ metastatic breast cancer. Clinically, T-DXd has demonstrated antitumor activity in both HER2+ and HER2-low cancers. Due to the role of PARP1 in resolution of DNA damage induced by topoisomerase I trapping, we tested the combination of the next generation PARP1-selective inhibitor AZD5305 with T-DXd.
Methods: We evaluated the antiproliferative ability of the combination of T-DXd with AZD5305 in a panel of 27 breast cancer cell lines in an in vitro 7-day viability assay. The combination was also evaluated in vivo in two non-HRD HER2+ models, KPL4 (Breast) and NCI-N87 (Gastric) at doses of 3mg/kg and 10mg/kg Q3W for T-DXd combined with 0.01, 0.1, and 1 mg/kg QD of AZD5305. To evaluate the specificity of the combination activity in tumor cells (vs normal tissue), we further evaluated the combination in a human 2D in vitro bone marrow progenitor assay.
Results: We found that the combination had enhanced in vitro cell killing activity over single agents in 8/27 of the models tested. The benefit was present in both Homologous Recombination Deficient (HRD) as well as Homologous Recombination proficient, suggesting it does not depend on HRD (as defined by mutations in DNA damage repair genes). Mechanistically, T-DXd activated PARP and the combination of T-DXd with AZD5305 abrogated PARP1 auto-parylation, leading to enhanced DNA damage (gH2AX, pRPA-S4/8) and cell death (cCasp3). In vivo, the combination was well tolerated and more active than monotherapy of either compound in both KPL4 (at 30 days the growth inhibition was 95% at 10mg/kg T-DXd, 10% at 1mg/kg AZD5305, and 100% TGI with 97% regression with T-DXd + AZD5305) and NCI-N87 (at 41 days TGI of 74% with 10mg/kg T-DXd, 47% with 1mg/kg AZD5305, and 100% TGI with 40% regression for T-DXd + AZD5305; p<0.0001). In an in vitro human bone marrow assay, the combination demonstrated modest enhancement over monotherapy activity (average Loewe Synergy Score of 3.1). We tested alternative doses and schedules of the combination in KPL4 in vivo. We found that reducing the dose of AZD5305 as low as 0.01mg/kg resulted in combination benefit (100% TGI with 78% regression for combination versus 0% TGI for monotherapy on day 30). Further, 7-day delay of 0.01mg/kg AZD5305 in combination with 10mg/kg T-DXd also provided greater activity (>100% TGI with 72% regression on day 30) vs. monotherapy T-DXd alone (95% TGI).
Conclusions: These results suggest that T-DXd combined with the next generation PARP1 inhibitor AZD5305 is a potentially active combination, with preclinical activity demonstrated in HRD and HR proficient models. Further, the dose and scheduling may warrant exploration clinically to optimize therapeutic index.
Citation Format: Yann Wallez, Theresa Proia, Elisabetta Leo, Laura Bradshaw, Zena Wilson, Joe’l Owusu, Azadeh Cheraghchi-Bashi-Astaneh, Anna Staniszewska, Mark O’Connor, Sabina Cosulich, Jerome Mettetal. Activity and tolerability of combination of trastuzumab deruxtecan with the next generation PARP1-selective inhibitor AZD5305 in preclinical models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1142.
Collapse
|
10
|
Jamal K, Staniszewska A, Gordon J, Wen S, McGrath F, Dowdell G, Kabbabe D, illuzzi G, Griffin M, Davies BR, Hamerlik P. Abstract 2609: AZD9574 is a novel, brain penetrant PARP-1 selective inhibitor with activity in an orthotopic, intracranial xenograft model with aberrant DNA repair. Cancer Res 2022. [DOI: 10.1158/1538-7445.am2022-2609] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The Poly (ADP-ribose) polymerase (PARP) family has numerous essential functions in cellular processes such as transcription, chromatin remodelling, DNA damage response and repair as well as apoptosis. PARP inhibition blocks base excision repair and results in conversion of SSBs to DNA double-strand break (DSBs). DSBs are the most deleterious form of DNA damage that can be generated by exogenous DNA damaging agents or endogenous replication stress. DSBs can be repaired by homologous recombination repair (HRR) or non-homologous end joining (NHEJ). The physiological importance of HRR is underscored by the observation of genomic instability in HRR-deficient (HRD+) cells and, importantly, the association of cancer predisposition and developmental defects with mutations in HRR genes. PARP1 and PARP2 are required for SSB repair, while PARP1 is also involved in the repair of DNA double-strand breaks (DSBs) and replication fork damage. Recent reports suggest the PARP1 inhibition is sufficient to elicit an anti-proliferative effect and that PARP2 is essential for the survival of hematopoietic stem and progenitor cells in animal models.AZD9574 is a novel brain penetrant PARP1 inhibitor that acts by selectively inhibiting and trapping PARP1 at the sites of SSBs. AZD9574 exhibited >8000-fold selectivity for PARP1 compared to PARP2 and other members of the PARP family (PARP2, PARP3, PARP5a and PARP6) in biochemical assays. While AZD9574 inhibited PARP1 enzymatic activity in all tested cell lines irrespective of the HRR status (IC50 range between 0.3 - 2 nM), colony formation assay in isogenic cell lines pairs confirmed higher potency and selectivity towards HRD+ models (DLD1 BRCA2-/-; SKOV-3 BRCA2-/- and SKOV-3 PALB2-/-). For example, AZD9574 IC50 in the BRCA2-/- DLD1 cells was 1.38 nM compared to IC50 > 40 µM BRCA2wt cells, which corresponds to a ~20,000-fold greater efficacy in the BRCA2-/-cells (ratio of AZD9574 IC50 in BRCA2wt divided by BRCA2-/-) compared to the wild type parental line. In vivo, AZD9574 demonstrated dose-dependent efficacy in a BRCA1 mutant MDA-MB-436 subcutaneous xenograft model. Anti-tumour effects of AZD9574 were manifested by pronounced growth regressions that were durable after treatment withdrawal. An intracranial xenograft model of breast cancer brain metastases was developed to assess the efficacy of AZD9574 in the context of blood-brain barrier penetrance. Treatment of animals with established intracranial lesions using a dose of 3 mg/kg AZD9574 showed sustained tumour growth suppression resulting in a significantly extended survival of tumour-bearing mice. Collectively, we believe that our data support the development of AZD9574 as a potential therapy for patients with HRD+ breast cancer whose disease has spread to the brain.
Citation Format: Kunzah Jamal, Anna Staniszewska, Jacob Gordon, Shenghua Wen, Frank McGrath, Gregory Dowdell, Dominic Kabbabe, Giuditta illuzzi, Matthew Griffin, Barry R. Davies, Petra Hamerlik. AZD9574 is a novel, brain penetrant PARP-1 selective inhibitor with activity in an orthotopic, intracranial xenograft model with aberrant DNA repair [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2609.
Collapse
|
11
|
Ghosh A, Hande SM, Balazs A, Barratt D, Cosulich S, Davies B, Degorce S, Embrey K, Gill S, Gunnarsson A, Illuzzi G, Johnström P, Lane J, Larner C, Lawrence R, Leo E, Madin A, Martin E, McWilliams L, O’Connor L, O’Connor M, Orme J, Pachl F, Packer M, Pike A, Rawlins P, Schimpl M, Schou M, Staniszewska A, Yang W, Yates J, Zhang A, Zheng X, Fawell S, Hamerlik P, Johannes J. Abstract 6302: Structure-based and property-based drug design of AZD9574, a CNS penetrant PARP1 selective inhibitor and trapper. Cancer Res 2022. [DOI: 10.1158/1538-7445.am2022-6302] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
PARP inhibitors exploit defects in DNA repair pathways to selectively target cancerous cells via PARP1 catalytic inhibition and PARP1 trapping onto the DNA. All known clinical PARP1 inhibitors bind at the same site at the catalytic center of the enzyme. However, despite this resemblance they show immensely different outcomes in terms of response rate in the clinic due to their varying degree of PARP trapping ability. Moreover, the first-generation PARP inhibitors were not optimized for selectivity across the PARP family potentially driving undesirable side effects, including intestinal toxicity from tankyrase inhibition or hematological toxicity from PARP2 inhibition. There has been strong rationale for the use of PARP inhibitors in neuro-oncology. However, the first-generation PARP inhibitors have limited CNS distribution as these drugs were not designed for brain penetration. Recently AstraZeneca has reported the discovery of AZD5305, a next generation PARP1 selective inhibitor and PARP1-DNA trapper which was not designed with a CNS penetrant profile. Given the unmet need of a brain penetrant PARP1 inhibitor, we set out to identify a highly potent and selective PARP1 inhibitor and trapper with CNS profile. In our next generation PARP1 inhibitor, we sought to retain the profile of AZD5305 and lower the efflux for CNS penetration. Despite the challenge of narrow SAR, we successfully used the structure- and property-based design approach to identify a brain penetrant PARP1 inhibitor and PARP1-DNA trapper. We used multiple medicinal chemistry maneuvers such as masking the hydrogen bond donors and core modifications to lower the efflux in order to achieve brain penetration. Further optimization of the nicotinamide mimetic core for potency and metabolic stability led us to the discovery of AZD9574.AZD9574 shows improved selectivity for PARP1 over PARP2 vs AZD5305 and retains its excellent selectivity over other PARP family members. It has low efflux in Caco2, MDCK-MDR1, and MDCK-MDR1-BCRP permeability assays and it also showed CNS penetration in rat and cynomolgus monkey. AZD9574 has excellent secondary pharmacology and acceptable physicochemical properties and good PK in preclinical species.In vitro, AZD9574 selectively inhibits the growth of BRCAm cell lines. Importantly, AZD9574 showed efficacy in an intracranial BRCA1m MDA-MB-436 xenograft model at doses of 3, 10 and 30 mg/kg QD, significantly extending the survival of tumor-bearing mice compared to vehicle control arm.In summary, AZD9574 is a next generation selective PARP1 inhibitor and trapper with CNS penetration. This profile makes it an ideal candidate for treating CNS malignancies or brain metastases that have a dependence on PARP inhibition either as single agent or in combination with other therapies.
Citation Format: Avipsa Ghosh, Sudhir M. Hande, Amber Balazs, Derek Barratt, Sabina Cosulich, Barry Davies, Sébastien Degorce, Kevin Embrey, Sonja Gill, Anders Gunnarsson, Giuditta Illuzzi, Peter Johnström, Jordan Lane, Carrie Larner, Rachel Lawrence, Elisabetta Leo, Andrew Madin, Elizabeth Martin, Lisa McWilliams, Lenka O’Connor, Mark O’Connor, Jonathan Orme, Fiona Pachl, Martin Packer, Andy Pike, Philip Rawlins, Marianne Schimpl, Magnus Schou, Anna Staniszewska, Wenzhan Yang, James Yates, Andrew Zhang, XiaoLa Zheng, Stephen Fawell, Petra Hamerlik, Jeffrey Johannes. Structure-based and property-based drug design of AZD9574, a CNS penetrant PARP1 selective inhibitor and trapper [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 6302.
Collapse
Affiliation(s)
| | | | | | - Derek Barratt
- 2AstraZeneca Pharmaceuticals, Cambridge, United Kingdom
| | | | - Barry Davies
- 2AstraZeneca Pharmaceuticals, Cambridge, United Kingdom
| | | | - Kevin Embrey
- 2AstraZeneca Pharmaceuticals, Cambridge, United Kingdom
| | - Sonja Gill
- 2AstraZeneca Pharmaceuticals, Cambridge, United Kingdom
| | | | | | | | - Jordan Lane
- 2AstraZeneca Pharmaceuticals, Cambridge, United Kingdom
| | - Carrie Larner
- 2AstraZeneca Pharmaceuticals, Cambridge, United Kingdom
| | | | | | - Andrew Madin
- 2AstraZeneca Pharmaceuticals, Cambridge, United Kingdom
| | | | | | | | - Mark O’Connor
- 2AstraZeneca Pharmaceuticals, Cambridge, United Kingdom
| | - Jonathan Orme
- 2AstraZeneca Pharmaceuticals, Cambridge, United Kingdom
| | | | - Martin Packer
- 5AstraZeneca Pharmaceuticals, Cambridg, United Kingdom
| | - Andy Pike
- 2AstraZeneca Pharmaceuticals, Cambridge, United Kingdom
| | | | | | | | | | | | - James Yates
- 2AstraZeneca Pharmaceuticals, Cambridge, United Kingdom
| | | | | | | | | | | |
Collapse
|
12
|
Słoniewski R, Dąbrowska-Bender M, Religioni U, Fronczak A, Staniszewska A, Duda-Zalewska A, Milewska M, Kędzierska M, Matkowski RA, Dykowska G, Słoniewska A, Kupiecka A. A Comparative Analysis of Quality of Life in Women Diagnosed with Breast and Ovarian Cancer. Int J Environ Res Public Health 2022; 19:ijerph19116705. [PMID: 35682288 PMCID: PMC9180185 DOI: 10.3390/ijerph19116705] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 04/04/2022] [Revised: 05/24/2022] [Accepted: 05/26/2022] [Indexed: 11/16/2022]
Abstract
Background: Previous studies showed that cancer significantly reduces the quality of life of patients. The purpose of this study was to analyze changes in the quality of life of women diagnosed with ovarian and breast cancer after surgical treatment followed by adjuvant cancer therapy. Methods: The study covered 220 women diagnosed with ovarian (n = 89) or breast cancer (n = 131) after surgical treatment followed by adjuvant cancer therapy (chemotherapy, radiotherapy, hormone therapy). The tools used to measure the patients’ quality of life were the standardized EORTC QLQ-C30 questionnaire, the QLQ-BR23 module for breast cancer and the QLQ-OV28 module for ovarian cancer. Results: The subjective assessment of the health and quality of life of the women was carried out using the EORTC QLQ-C30 questionnaire and the QLQ-OV28 and QLQ-BR23 modules. Women with breast cancer rated their health higher than women with ovarian cancer. The health assessment performed by the patients was not related to the type of cancer (p > 0.05). They experienced pain, dyspnea and weakness regardless of the cancer location. Moreover, women’s health status had a clinically significant impact on their family and social life, although no statistically significant differences were found between the two groups (p > 0.05). Whilst the patients with breast cancer rated their quality of life and health higher than the patients with ovarian cancer, the differences were not statistically significant (p > 0.05). Conclusions: Changes in the quality of life of women with breast and ovarian cancer concern the physical sphere, hobbies, fatigue/rest, pain, family and social spheres, and material conditions. It is necessary to support specialists at every stage of treatment of these patients, which may improve the results of the treatment and patients’ perception of health and quality of life.
Collapse
Affiliation(s)
- Robert Słoniewski
- Department of Public Health, Medical University of Warsaw, 02-091 Warsaw, Poland; (A.F.); (A.D.-Z.)
- Correspondence:
| | - Marta Dąbrowska-Bender
- Department of Clinical Dietetics, Medical University of Warsaw, 02-091 Warsaw, Poland; (M.D.-B.); (M.M.)
| | - Urszula Religioni
- School of Public Health, Centre of Postgraduate Medical Education of Warsaw, 01-813 Warsaw, Poland;
| | - Adam Fronczak
- Department of Public Health, Medical University of Warsaw, 02-091 Warsaw, Poland; (A.F.); (A.D.-Z.)
| | - Anna Staniszewska
- Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, 02-091 Warsaw, Poland;
| | - Aneta Duda-Zalewska
- Department of Public Health, Medical University of Warsaw, 02-091 Warsaw, Poland; (A.F.); (A.D.-Z.)
| | - Magdalena Milewska
- Department of Clinical Dietetics, Medical University of Warsaw, 02-091 Warsaw, Poland; (M.D.-B.); (M.M.)
| | - Magdalena Kędzierska
- Department of Chemotherapy, Medical University of Lodz and Copernicus Memorial Hospital, CCC & T, 90-419 Lodz, Poland;
| | - Rafał Adam Matkowski
- Department of Oncology, Wrocław Medical University, Lower Silesian Oncology, Pulmonology and Hematology Center, 53-413 Wroclaw, Poland;
| | - Grażyna Dykowska
- Department of Health Economics and Medical Law, Medical University of Warsaw, 02-091 Warsaw, Poland;
| | | | - Anna Kupiecka
- OnkoCafe Foundation—“Together Better”, 04-175 Warsaw, Poland;
| |
Collapse
|
13
|
Matryba P, Gawalski K, Ciesielska I, Horvath A, Bartoszewicz Z, Sienko J, Ambroziak U, Malesa-Tarasiuk K, Staniszewska A, Golab J, Krenke R. The Influence of Time of Day of Vaccination with BNT162b2 on the Adverse Drug Reactions and Efficacy of Humoral Response against SARS-CoV-2 in an Observational Study of Young Adults. Vaccines (Basel) 2022; 10:vaccines10030443. [PMID: 35335074 PMCID: PMC8954058 DOI: 10.3390/vaccines10030443] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2022] [Revised: 03/05/2022] [Accepted: 03/10/2022] [Indexed: 02/05/2023] Open
Abstract
An increasing body of evidence from both academic and clinical studies shows that time-of-day exposure to antigens might significantly alter and modulate the development of adaptive immune responses. Considering the immense impact of the COVID-19 pandemic on global health and the diminished efficacy of vaccination in selected populations, such as older and immunocompromised patients, it is critical to search for the most optimal conditions for mounting immune responses against SARS-CoV-2. Hence, we conducted an observational study on 435 healthy young adults vaccinated with two doses of BNT162b2 (Pfizer-BioNTech) vaccine to determine whether time-of-day of vaccination influences either the magnitude of humoral response or number of adverse drug reactions (ADR) being reported. We found no significant differences between morning and afternoon vaccination in terms of both titers of anti-Spike antibodies and frequency of ADR in the studied population. In addition, our analysis of data on the occurrence of ADR in 1324 subjects demonstrated that the second administration of vaccine in those with previous SARS-CoV-2 infection was associated with lower incidence of ADR. In aggregate, vaccination against COVID-19 with two doses of BNT162b2 mRNA vaccine is presumed to generate an equally efficient anti-Spike humoral response.
Collapse
Affiliation(s)
- Paweł Matryba
- Department of Immunology, Medical University of Warsaw, 02-097 Warsaw, Poland; (K.G.); (J.G.)
- The Doctoral School of the Medical University of Warsaw, Medical University of Warsaw, 02-097 Warsaw, Poland
- Correspondence:
| | - Karol Gawalski
- Department of Immunology, Medical University of Warsaw, 02-097 Warsaw, Poland; (K.G.); (J.G.)
| | - Iga Ciesielska
- Department of Internal Medicine, Pulmonary Diseases and Allergy, Medical University of Warsaw, 02-097 Warsaw, Poland; (I.C.); (K.M.-T.); (R.K.)
| | - Andrea Horvath
- Department of Pediatrics, Medical University of Warsaw, 02-097 Warsaw, Poland;
| | - Zbigniew Bartoszewicz
- Department of Internal Medicine and Endocrinology, Medical University of Warsaw, 02-097 Warsaw, Poland; (Z.B.); (U.A.)
| | - Jacek Sienko
- 2nd Department of Obstetrics and Gynecology, Medical University of Warsaw, 02-097 Warsaw, Poland;
| | - Urszula Ambroziak
- Department of Internal Medicine and Endocrinology, Medical University of Warsaw, 02-097 Warsaw, Poland; (Z.B.); (U.A.)
| | - Karolina Malesa-Tarasiuk
- Department of Internal Medicine, Pulmonary Diseases and Allergy, Medical University of Warsaw, 02-097 Warsaw, Poland; (I.C.); (K.M.-T.); (R.K.)
| | - Anna Staniszewska
- Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, 02-097 Warsaw, Poland;
| | - Jakub Golab
- Department of Immunology, Medical University of Warsaw, 02-097 Warsaw, Poland; (K.G.); (J.G.)
| | - Rafał Krenke
- Department of Internal Medicine, Pulmonary Diseases and Allergy, Medical University of Warsaw, 02-097 Warsaw, Poland; (I.C.); (K.M.-T.); (R.K.)
| |
Collapse
|
14
|
Dellavedova G, Decio A, Staniszewska A, Leo E, Giavazzi R, Bani MR. Abstract P217: The next generation PARP inhibitor AZD5305 is active in a broad range of pre-clinical models of ovarian cancer. Mol Cancer Ther 2021. [DOI: 10.1158/1535-7163.targ-21-p217] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Since the approval of poly (ADP-ribose) polymerase inhibitors (PARPi) for BRCA-mutated ovarian cancer patients, different PARPi have been developed and have shown efficacy in homologous recombination deficient (HRD) tumours. These first-generation drugs inhibit both PARP1 and PARP2 (as well as other PARP family members) and present undesirable adverse effects, such as haematological and intestinal toxicity, that restricted their use especially in combination with already poorly tolerated chemotherapeutic agents. Here, patient-derived ovarian cancer xenografts (OC-PDXs) were used i) to evaluate the dose response efficacy of AZD5305, a next generation, potent and selective PARP1 inhibitor and ii) to investigate the effect of the combination with carboplatin, a standard-of-care treatment for ovarian cancer patients. AZD5305 was administered orally (po) once daily (QD) for 8 weeks as monotherapy (0.1, 1 and 10 mg/kg) and in combination with carboplatin (CPT) dosed intravenously (35 mg/kg; Q7x4). Two BRCA1 mutated (HOC106 and HOC107) and a BRCA wild-type (HOC84) OC-PDXs (all TP53 mutated) were implanted subcutis and the effect of treatments on tumour growth evaluated. AZD5305 dosed at 0.1, 1 and 10 mg/kg to mice bearing HOC106 tumours, inhibited tumours growth in a dose dependent manner. Administered in combination at 0.1 and 1 mg/kg, AZD5305 potentiated the effect of carboplatin, causing a significant and sustained regression of HOC106 tumours. The anti-tumour efficacy was also evident against the PARPi-resistant OC-PDX HOC107, whereby the tumour growth was inhibited by AZD5305 at 1 and 10 mg/kg dose. Combined with carboplatin, AZD5305 stabilized the growth of HOC107 tumours at doses as low as 0.1 mg/kg that on its own was not effective. As expected, none of the treatments affected the growth of the BRCA wild-type HOC84 (PARPi and carboplatin resistant OC-PDX). Overall, AZD5305 a next generation PARP1-selective inhibitor and trapper, shows improved efficacy and tolerability in combination with chemotherapy compared to first generation, PARP1/2 inhibitors, making it a promising clinical candidate for the treatment of ovarian cancer.
Citation Format: Giulia Dellavedova, Alessandra Decio, Anna Staniszewska, Elisabetta Leo, Raffaella Giavazzi, Maria Rosa Bani. The next generation PARP inhibitor AZD5305 is active in a broad range of pre-clinical models of ovarian cancer [abstract]. In: Proceedings of the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics; 2021 Oct 7-10. Philadelphia (PA): AACR; Mol Cancer Ther 2021;20(12 Suppl):Abstract nr P217.
Collapse
Affiliation(s)
| | - Alessandra Decio
- 1Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy,
| | | | | | | | - Maria Rosa Bani
- 1Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy,
| |
Collapse
|
15
|
Olejniczak D, Klimiuk K, Religioni U, Staniszewska A, Panczyk M, Nowacka A, Mularczyk-Tomczewska P, Krzych-Fałta E, Korcala-Wichary A, Balwicki Ł. Willingness to Oppose Smoking among Pregnant Women. Int J Environ Res Public Health 2021; 18:11636. [PMID: 34770159 PMCID: PMC8583594 DOI: 10.3390/ijerph182111636] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 08/30/2021] [Revised: 10/21/2021] [Accepted: 11/02/2021] [Indexed: 11/16/2022]
Abstract
Even though smoking causes numerous threats to the developing foetus, it is the most common addiction in Polish women of reproductive age. Most studies undertake to examine the subject of opposing second-hand smoking or creating tools to reprimand pregnant women more effectively using a qualitative methodology. The study aimed to determine the profile of a pregnant woman who is willing to oppose the smoking of another pregnant woman. The research was conducted using an original multiple-choice questionnaire. The survey was shared on websites for expecting parents. Completed questionnaires were collected from 11,448 pregnant women. The Wald test for logistic regression was used for statistical analysis. Predictors of whether someone would draw another pregnant women's attention to the fact that smoking is harmful were: intellectual work (OR 1.136; p-value 0.020) and currently being a student (OR 1.363; p-value 0.004), involvement of the child's father (OR 1.377; p-value < 0.001), contact with social campaigns (OR 1.150; p-value 0.005) and knowledge about the consequences of smoking, as well as talking to the midwife about the harmfulness of cigarettes during pregnancy (OR 1.655; p-value < 0.001). Interpersonal relationships leave scope for public health interventions. It is worth enhancing criticism against smoking by specialists through information and education campaigns.
Collapse
Affiliation(s)
- Dominik Olejniczak
- Department of Public Health, Faculty of Health Science, Medical University of Warsaw, 02-091 Warsaw, Poland; (D.O.); (P.M.-T.)
| | - Krzysztof Klimiuk
- Faculty of Medicine, Medical University of Gdańsk, 80-210 Gdańsk, Poland
| | - Urszula Religioni
- Collegium of Business Administration, Warsaw School of Economics, 02-554 Warsaw, Poland;
| | - Anna Staniszewska
- Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, 02-091 Warsaw, Poland;
| | - Mariusz Panczyk
- Department of Education and Research of Health Sciences, Faculty of Health Sciences, Medical University of Warsaw, Zwirki Wigury 81, 01-580 Warsaw, Poland;
| | - Agnieszka Nowacka
- Department of Obstetrics and Gynecology Didactics, Faculty of Health Sciences, Medical University of Warsaw, 02-091 Warsaw, Poland;
| | - Paulina Mularczyk-Tomczewska
- Department of Public Health, Faculty of Health Science, Medical University of Warsaw, 02-091 Warsaw, Poland; (D.O.); (P.M.-T.)
| | - Edyta Krzych-Fałta
- Nursing Basics Facility, Medical University of Warsaw, 02-091 Warsaw, Poland;
| | - Anna Korcala-Wichary
- Health Promotion Section, Students’ Scientific Public Health Association, Medical University of Warsaw, 02-091 Warsaw, Poland;
| | - Łukasz Balwicki
- Department of Public Health and Social Medicine, Medical University of Gdańsk, 80-210 Gdańsk, Poland;
| |
Collapse
|
16
|
Sacco A, Federico C, Todoerti K, Ziccheddu B, Palermo V, Giacomini A, Ravelli C, Maccarinelli F, Bianchi G, Belotti A, Ribolla R, Favasuli V, Revenko AS, Macleod AR, Willis B, Cai H, Hauser J, Rooney C, Willis SE, Martin PL, Staniszewska A, Ambrose H, Hanson L, Cattaneo C, Tucci A, Rossi G, Ronca R, Neri A, Mitola S, Bolli N, Presta M, Moschetta M, Ross S, Roccaro AM. Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activity. Blood 2021; 138:1705-1720. [PMID: 34077955 PMCID: PMC9710471 DOI: 10.1182/blood.2020010572] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2020] [Accepted: 05/07/2021] [Indexed: 12/14/2022] Open
Abstract
Alterations in KRAS have been identified as the most recurring somatic variants in the multiple myeloma (MM) mutational landscape. Combining DNA and RNA sequencing, we studied 756 patients and observed KRAS as the most frequently mutated gene in patients at diagnosis; in addition, we demonstrated the persistence or de novo occurrence of the KRAS aberration at disease relapse. Small-molecule inhibitors targeting KRAS have been developed; however, they are selective for tumors carrying the KRASG12C mutation. Therefore, there is still a need to develop novel therapeutic approaches to target the KRAS mutational events found in other tumor types, including MM. We used AZD4785, a potent and selective antisense oligonucleotide that selectively targets and downregulates all KRAS isoforms, as a tool to dissect the functional sequelae secondary to KRAS silencing in MM within the context of the bone marrow niche and demonstrated its ability to significantly silence KRAS, leading to inhibition of MM tumor growth, both in vitro and in vivo, and confirming KRAS as a driver and therapeutic target in MM.
Collapse
Affiliation(s)
- Antonio Sacco
- Clinical Research Development and Phase I Unit, CREA Laboratory, ASST Spedali Civili di Brescia, Brescia, Italy
| | - Cinzia Federico
- Clinical Research Development and Phase I Unit, CREA Laboratory, ASST Spedali Civili di Brescia, Brescia, Italy
| | - Katia Todoerti
- Hematology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - Bachisio Ziccheddu
- Department of Molecular Biotechnologies and Health Sciences, University of Turin, Turin, Italy
| | - Valentina Palermo
- Clinical Research Development and Phase I Unit, CREA Laboratory, ASST Spedali Civili di Brescia, Brescia, Italy
| | - Arianna Giacomini
- Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy
| | - Cosetta Ravelli
- Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy
| | - Federica Maccarinelli
- Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy
| | - Giada Bianchi
- Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
| | - Angelo Belotti
- Hematology, ASST Spedali Civili di Brescia, Brescia, Italy
| | | | - Vanessa Favasuli
- Hematology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
| | | | | | | | | | - Joana Hauser
- Oncology R &D, AstraZeneca, Cambridge, United Kingdom; and
| | - Claire Rooney
- Oncology R &D, AstraZeneca, Cambridge, United Kingdom; and
| | | | | | | | - Helen Ambrose
- Oncology R &D, AstraZeneca, Cambridge, United Kingdom; and
| | - Lyndsey Hanson
- Oncology R &D, AstraZeneca, Cambridge, United Kingdom; and
| | | | | | - Giuseppe Rossi
- Hematology, ASST Spedali Civili di Brescia, Brescia, Italy
| | - Roberto Ronca
- Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy
| | - Antonino Neri
- Hematology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
| | - Stefania Mitola
- Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy
| | - Niccolò Bolli
- Hematology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
| | - Marco Presta
- Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy
| | | | - Sarah Ross
- Oncology R &D, AstraZeneca, Cambridge, United Kingdom; and
| | - Aldo M. Roccaro
- Clinical Research Development and Phase I Unit, CREA Laboratory, ASST Spedali Civili di Brescia, Brescia, Italy
| |
Collapse
|
17
|
Marcinkiewicz A, Śliż DI, Olejniczak D, Price S, Kałużny P, Staniszewska A, Jankowski P, Mamcarz A, Walusiak-Skorupa J, Hanke W. Dyslipidaemia, carbohydrate metabolism disorders and arterial hypertension detected in academic employees during examinations in occupational medicine. Ann Agric Environ Med 2021; 28:314-318. [PMID: 34184516 DOI: 10.26444/aaem/128017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/13/2023]
Abstract
INTRODUCTION Many people have CVD risk factors without realising it and it is important to recognise the risk factors as soon as possible. Periodic examinations are a mandatory form of control for all employes in Poland. They provide an excellent opportunity to screen for the most common civilization diseases in the population. OBJECTIVE The aim of this study is to evaluate the prevalence of dyslipidaemia, hyperglycaemia and hypertension among academics in a Polish university, and to compare the results between postdoctoral fellows and other academics. MATERIAL AND METHODS The study group were postdoctoral fellows (HAB; N=135, 53 females) and other academics (NHAB; N=286, 179 females) over the age of 40 who reported for a periodic occupational medical check-up. Fasting blood samples were drawn, serum glucose, lipids and blood pressure (BP) were measured. RESULTS The mean age was 56.7 (SD 9.8) in HAB and 49.8 (SD 8.1) in NHAB. Mean systolic BP and glycaemia were significantly higher in male HAB group than male NHAB (135.8 vs 130.9 mmHg and 6.0 vs 5.6 mmol/l, respectively). The relationship in females was non-significant. The age-adjusted odds ratios (OR [95% CI]) of having elevated low density lipoprotein cholesterol, total cholesterol, glucose and blood pressure in male HAB vs male NHAB were 0.61 [0.32. 1.16], 0.64 [0.33, 1.23], 1.52 [0.80, 2.88] and 2.11 [0.88, 5.23], and in female HAB vs female NHAB - 0.59 [0.31, 1.12], 0.64 [0.32, 1.26], 0.87 [0.40, 1.79] and 1.86 [0.70, 4.68], respectively. CONCLUSIONS Adequately planned occupational medicine examinations provide an opportunity to diagnose dyslipidaemia, hyperglycaemia, or high BP in all groups of employees, including highly educated academics.
Collapse
Affiliation(s)
- Andrzej Marcinkiewicz
- Department of Occupational Diseases and Environmental Health, Nofer Institute of Occupational Medicine, Łódź, Poland
| | - Daniel Ireneusz Śliż
- III Department of Internal Diseases and Cardiology, Medical University of Warsaw, Poland
| | | | - Szymon Price
- Department of Internal Medicine and Cardiology, Municipal Hospital in Olsztyn, Poland
| | - Paweł Kałużny
- Department of Environmental Epidemiology, Nofer Institute of Occupational Medicine, Łódź, Poland
| | - Anna Staniszewska
- Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Poland
| | - Piotr Jankowski
- 1st Department of Cardiology, Interventional Electrocardiology and Hypertension, Institute of Cardiology, Jagiellonian University Medical College, Kraków, Poland
| | - Artur Mamcarz
- III Department of Internal Diseases and Cardiology, Medical University of Warsaw, Poland
| | - Jolanta Walusiak-Skorupa
- Department of Occupational Diseases and Environmental Health, Nofer Institute of Occupational Medicine, Łódź, Poland
| | - Wojciech Hanke
- Department of Environmental Epidemiology, Nofer Institute of Occupational Medicine, Łódź, Poland
| |
Collapse
|
18
|
Abstract
INTRODUCTION The increasing prevalence of diabetes mellitus and advances in endovascular therapies continue to have an impact on the epidemiology and management of lower extremity arterial disease. This study describes trends in lower extremity revascularisation and major lower limb amputation in NHS England over the past two decades (2000-2019). METHODS Numbers of lower extremity endovascular interventions, open surgical procedures and major lower limb amputations performed in NHS England between 2000 and 2019 were extracted from publicly available hospital admitted patient care activity reports. Trends in intervention were assessed with linear regression models and chi-square tests for trend. RESULTS Over this period, 527,131 revascularisations and 92,053 amputations were performed. The mean age of patients was 67.5 years (standard deviation 1.6 years) and 65.3% were male. The number of lower limb revascularisation procedures increased by 402.4 units/year (95% confidence interval, CI, 290.1-514.6, p < 0.001). The number of endovascular interventions rose by 43.5% (10,912 in 2000 vs 15,657 in 2019; β = 359.5.0, 95% CI 279.3-439.8, p < 0.001) compared with no significant increase in the number of open surgical procedures (8,483 in 2000 vs 7,872 in 2019; β = 42.8, 95% CI -8.3 to 94.0, p = 0.095). The number of major lower limb amputations has decreased by 9.4% (5,418 in 2000 vs 4,907 in 2019; β = -31.0; 95% CI -49.6 to -12.5, R2 = 0.42, p = 0.003). CONCLUSIONS There has been a significant increase in the rate of lower limb revascularisation procedures associated with decreased numbers of major lower limb amputations over the past two decades. These changes in overall trends may affect both service provision and vascular surgery training planning.
Collapse
Affiliation(s)
- A Staniszewska
- Academic Section of Vascular Surgery, Department of Surgery and Cancer, Imperial College London, London, UK
| | - M Gimzewska
- Academic Section of Vascular Surgery, Department of Surgery and Cancer, Imperial College London, London, UK
| | - S Onida
- Academic Section of Vascular Surgery, Department of Surgery and Cancer, Imperial College London, London, UK
| | - T Lane
- Academic Section of Vascular Surgery, Department of Surgery and Cancer, Imperial College London, London, UK
| | - A H Davies
- Academic Section of Vascular Surgery, Department of Surgery and Cancer, Imperial College London, London, UK
| |
Collapse
|
19
|
Staniszewska A, Mąka A, Religioni U, Olejniczak D, Juszczyk G, Gierczyński R, Marcinkiewicz A. Patients with epilepsy as drivers in Poland. Med Pr 2021; 72:341-350. [PMID: 33835110 DOI: 10.13075/mp.5893.01079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
Abstract
BACKGROUND Drivers suffering from epilepsy are commonly regarded as a threat to road safety. However, inability to use their own means of transport very often implies specific professional effects and lowers the quality of life. The aim of this study was to analyze the driving status of patients with epilepsy in Poland. MATERIAL AND METHODS The prospective study was performed using an independent questionnaire developed by the authors, consisting of 4 parts: 1) socio-demographic information, 2) clinical information, 3) driving information, and 4) opinions about patients with epilepsy as drivers. The study was conducted in November 2018-September 2019. A total of 188 patients completed this study. RESULTS More than one-quarter of the patients have a driving license. Among them, 35 individuals (accounting for 18.62% of the whole study group) said that they had received their driving license after the diagnosis of epilepsy. In 10 cases (5.32%), seizures occurred while the patients were driving and in 72 cases (38.30%) while they were traveling as passengers. Among all socio-clinical factors, having a driving license was conditioned by the marital status (p = 0.008) and education (p = 0.007). Other factors did not affect having a driving license or the time of obtaining the license (p > 0.05 for all cases). A relationship was observed between the occurrence of side effects of antiepileptic drugs and the occurrence of seizures while traveling as a car passenger (p = 0.001). Other factors did not affect the occurrence of epileptic seizures while traveling by car, either as a driver or a passenger (p > 0.05). CONCLUSIONS A significant proportion of the respondents were of the opinion that patients with epilepsy should not be allowed to obtain a driving license, which is probably related to concerns about the occurrence of epileptic seizures while driving. It is necessary to conduct a nationwide educational and information campaign on epilepsy in various aspects. Med Pr. 2021;72(4).
Collapse
Affiliation(s)
- Anna Staniszewska
- Medical University of Warsaw, Warsaw, Poland (Department of Experimental and Clinical Pharmacology)
| | - Agnieszka Mąka
- Military Institute of Medicine, Warsaw, Poland (Registration)
| | - Urszula Religioni
- Warsaw School of Economics, Warsaw, Poland (Collegium of Business Administration)
| | - Dominik Olejniczak
- Medical University of Warsaw, Warsaw, Poland (Department of Public Health)
| | - Grzegorz Juszczyk
- Medical University of Warsaw, Warsaw, Poland (Department of Public Health)
| | - Rafał Gierczyński
- National Institute of Public Health - National Institute of Hygiene, Warsaw, Poland (Division of Epidemiological and Environmental Safety)
| | - Andrzej Marcinkiewicz
- Nofer Institute of Occupational Medicine, Łódź, Poland (Department of Occupational Diseases and Environmental Health)
| |
Collapse
|
20
|
Marcinkiewicz A, Olejniczak D, Śliż D, Staniszewska A. The analysis of screening costs for hypercholesterolemia and hyperglycemia as part of obligatory examinations of employees. Int J Occup Med Environ Health 2021; 34:581-589. [PMID: 33749686 DOI: 10.13075/ijomeh.1896.01708] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
Abstract
OBJECTIVES High prevalence of hyperlipidemia and hyperglycemia requires searching for efficient and cost-effective methods of an early detection of these disorders. In Poland, obligatory employee medical check-ups could be a solution. MATERIAL AND METHODS The study included a group of university employees who underwent obligatory occupational examinations in 2018. Each employee had an additional lipid (unit cost: EUR 2.56) and blood glucose profile (EUR 0.93) done. The number of respondents involved in the study was 850 (340 males and 510 females), and their average age was 47 years (SD = 11 years). The education distribution was as follows: employees with secondary vocational and general education (physical, frontline and administrative workers): 176 (age: M±SD 50.3±10.3); employees with a university degree (academics with an M.Sc. or/and Ph.D. title and administrative staff): 535 (age: M±SD 43.6±9.8); and academics with a university title (Ass. Prof. and/or Prof.): 139 (age: M±SD 56.2±10.2). RESULTS Dyslipidemia (elevated total cholesterol ≥190 mg/dl and/or low-density lipoprotein cholesterol ≥115 mg/dl) was reported in 560 workers (65.9%). Hyperglycemia (fasting glucose ≥100 mg/dl) was observed in 256 workers (31%). The total cost of detecting a single case of dyslipidemia and hyperglycemia was EUR 3.88 and EUR 3.09, respectively. Divided by age groups, the costs were as follows: EUR 4.34 and EUR 4.53 in the age group <45 years; EUR 3.56 and EUR 2.42 in the age group ≥45 years. The costs of detecting a single case of dyslipidemia and hyperglycemia in employees aged ≥45 with regard to education were as follows: EUR 3.20 and EUR 2.07 in persons with secondary vocational and general education; EUR 3.40 and EUR 2.80 in persons with a university degree; and EUR 4.38 and EUR 2.28 in persons with a university title. CONCLUSIONS Due to the fact that the reporting rate for screening tests in the framework of occupational medicine is high, the cost of occupational screening tests for dyslipidemia and hyperglycemia can be lower than the cost of screening tests in the general population. Int J Occup Med Environ Health. 2021;34(5):581-9.
Collapse
Affiliation(s)
- Andrzej Marcinkiewicz
- Nofer Institute of Occupational Medicine, Łódź, Poland (Department of Occupational Diseases and Environmental Health)
| | - Dominik Olejniczak
- Public Health Committee of the Polish Academy of Sciences, Warsaw, Poland
| | - Daniel Śliż
- Public Health Committee of the Polish Academy of Sciences, Warsaw, Poland
| | - Anna Staniszewska
- Medical University of Warsaw, Warsaw, Poland (Department of Experimental and Clinical Pharmacology)
| |
Collapse
|
21
|
Lasota D, Pawłowski W, Krajewski P, Staniszewska A, Goniewicz K, Czerski R, Goniewicz M. Alcohol Intoxication and Suicide by Hanging in Poland. Alcohol Alcohol 2021; 55:278-283. [PMID: 32090236 DOI: 10.1093/alcalc/agaa013] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2020] [Revised: 01/20/2020] [Accepted: 01/30/2020] [Indexed: 11/13/2022] Open
Abstract
AIMS An integral part of the World Health Organization (WHO) plan to reduce suicide by 10% by 2020 is to identify areas and demographic groups, which should be priority target groups for preventive activities. This study aimed to present the demographic differences between victims of suicide by hanging in the Warsaw metropolitan area, in Poland, by examining the sobriety of victims. METHODS Data for analysis were obtained from the documentation of the Department of Forensic Medicine (DFM) at the Medical University of Warsaw (MUW). The retrospective analysis included 358 out of 466 victims of suicides by hanging in the Warsaw metropolitan area, in Poland, recorded in the DFM documentation covering 2011-2013. The data gathered included age, gender, the cause of death, a post-mortem examination as well as the level of ethanol in the blood and muscles of victims. RESULTS In both groups, men accounted for a larger percentage of victims than women, P = 0.068. In the no-alcohol group, the victims were older than in the alcohol group (47.52 ± 19.21 vs. 40.88 ± 12.77) (P < 0.001). The majority of the studied population were victims aged 25-34 (22.90%), mainly men (20.95%). Young men were also the largest group among victims in the alcohol group (28.33%). The most numerous age group among no-alcohol group were older victims aged 55-64 (19.10%), especially men (16.29%). CONCLUSION Regardless of sobriety, men were the largest group of suicide victims in the study population, which means that men die suicide more often than women. Differences in gender proportions are related to age. In the studied population, it was primarily young victims, mainly men. These are the groups that should be priority target groups for preventive activities aimed at reducing the number of suicides. The presence of ethanol in more than half of the victims of suicide in the study population indicates that alcohol is an important suicidal risk factor.
Collapse
Affiliation(s)
- Dorota Lasota
- Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Banacha 1b Street, 02097 Warsaw, Poland
| | - Witold Pawłowski
- Department of Disaster Medicine, Medical University of Warsaw, Żwirki i Wigury 61 Street, 02091 Warsaw, Poland
| | - Paweł Krajewski
- Department of Forensic Medicine, Medical University of Warsaw, Oczki 1 Street, 00001 Warsaw, Poland
| | - Anna Staniszewska
- Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Banacha 1b Street, 02097 Warsaw, Poland
| | | | - Robert Czerski
- Polish Air Force Academy, Dywizjonu 303 35 Street, 08521 Dęblin, Poland
| | - Mariusz Goniewicz
- Department of Emergency Medicine, Medical University of Lublin, Staszica 4-6 Street, 20081 Lublin, Poland
| |
Collapse
|
22
|
Brytek-Matera A, Sacre H, Staniszewska A, Hallit S. The Prevalence of Orthorexia Nervosa in Polish and Lebanese Adults and Its Relationship with Sociodemographic Variables and BMI Ranges: A Cross-Cultural Perspective. Nutrients 2020; 12:E3865. [PMID: 33348787 PMCID: PMC7767210 DOI: 10.3390/nu12123865] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2020] [Revised: 12/12/2020] [Accepted: 12/16/2020] [Indexed: 02/07/2023] Open
Abstract
The prevalence of orthorexia nervosa (ON) appears to be increasing, and more research into its cross-cultural aspects is required to provide culturally appropriate psychological treatment. Until now, there has been relatively little research published about ON across cultures. Therefore, the objectives of the present study were to determine: (1) the prevalence of ON in Polish and Lebanese adults and (2) the association between ON and sociodemographic variables and Body Mass Index (BMI) in two culturally different samples. One thousand two hundred and sixty-two adults participated in the present study (NPoland = 743 adults; NLebanon = 519 adults). The Düsseldorf Orthorexia Scale and the Eating Habits Questionnaire were used in the present study. Information about age, sex, anthropometry, and marital status was obtained from all participants as well. The Polish sample had an ON prevalence rate of 2.6%, while the Lebanese sample had an ON prevalence rate of 8.4%. No significant correlation was found between ON and age in both samples. A statistically significant difference was found between marital status and country on ON, with the highest mean score seen among Lebanese singles. In Lebanon, having a low of BMI ≤ 25 kg/m2 compared to a high BMI was significantly associated with lower ON tendencies, while this association was not significant among Polish participants. This study was the second to focus on the prevalence of ON in Western and non-Western countries and its association with sociodemographic characteristics and BMI ranges. Knowledge about ON and its correlates in diverse populations may inform the design of culturally tailored behavior change interventions and the development of culturally appropriate tools in various groups to improve their dietary patterns.
Collapse
Affiliation(s)
- Anna Brytek-Matera
- Institute of Psychology, University of Wroclaw, Dawida 1, 50-527 Wroclaw, Poland
| | - Hala Sacre
- Faculty of Medicine and Medical Sciences, Holy Spirit University of Kaslik (USEK), Jounieh, Lebanon; (H.S.); (S.H.)
| | - Anna Staniszewska
- Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, 02-091 Warsaw, Poland;
| | - Souheil Hallit
- Faculty of Medicine and Medical Sciences, Holy Spirit University of Kaslik (USEK), Jounieh, Lebanon; (H.S.); (S.H.)
- INSPECT-LB: Institut National de Santé Publique, Épidémiologie Clinique et Toxicologie-Liban, Beirut, Lebanon
| |
Collapse
|
23
|
Gizińska M, Staniszewska A, Kazek M, Koronkiewicz M, Kuryk Ł, Milner-Krawczyk M, Baran J, Borowiecki P, Staniszewska M. Antifungal polybrominated proxyphylline derivative induces Candida albicans calcineurin stress response in Galleria mellonella. Bioorg Med Chem Lett 2020; 30:127545. [PMID: 32931913 DOI: 10.1016/j.bmcl.2020.127545] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2020] [Revised: 09/02/2020] [Accepted: 09/04/2020] [Indexed: 11/29/2022]
Abstract
Candida albicans CNB1 plays a role in the response in vitro and in vivo to stress generated by PB-WUT-01, namely 1,3-dimethyl-7-(2-((1-(3-(perbromo-2H-benzo[d][1,2,3]triazol-2-yl)propyl)-1H-1,2,3-triazol-4-yl)methoxy)propyl)-1H-purine-2,6(3H,7H)-dione. The antifungal mechanism involved the calcineurin pathway-regulated genes SAP9-10. Galleria mellonella treated with PB-WUT-01 (at 0.64 µg/mg) showed limited candidiasis and remained within the highest survival rates. The molecular mode of action of PB-WUT-01 was rationalized by in silico docking studies toward both human and C. albicans calcineurin A (CNA) and calcineurin B (CNB) complexes, respectively. PB-WUT-01 acting as a calcineurin inhibitor in the C. albicans cells enhances the cells' susceptibility. Therefore it could be a suitable alternative treatment in patients with candidiasis.
Collapse
Affiliation(s)
| | - Anna Staniszewska
- Medical University of Lublin, Racławickie 1 Street, Lublin 20-059, Poland
| | - Michalina Kazek
- The Witold Stefański Institute of Parasitology, Polish Academy of Science, Twarda 51/55, Warsaw 00-818, Poland
| | | | - Łukasz Kuryk
- National Institute of Public Health-National Institute of Hygiene, Warsaw 00-791, Poland
| | | | - Joanna Baran
- Faculty of Chemistry, Warsaw University of Technology, Noakowskiego 3, Warsaw 00-664, Poland
| | - Paweł Borowiecki
- Faculty of Chemistry, Warsaw University of Technology, Noakowskiego 3, Warsaw 00-664, Poland.
| | - Monika Staniszewska
- Faculty of Chemistry, Warsaw University of Technology, Noakowskiego 3, Warsaw 00-664, Poland; Centre for Advanced Materials and Technologies, Warsaw University of Technology, Poleczki 19, Warsaw 02-822, Poland.
| |
Collapse
|
24
|
Mela A, Rdzanek E, Poniatowski ŁA, Jaroszyński J, Furtak-Niczyporuk M, Gałązka-Sobotka M, Olejniczak D, Niewada M, Staniszewska A. Economic Costs of Cardiovascular Diseases in Poland Estimates for 2015-2017 Years. Front Pharmacol 2020; 11:1231. [PMID: 33013357 PMCID: PMC7506040 DOI: 10.3389/fphar.2020.01231] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2020] [Accepted: 07/28/2020] [Indexed: 11/13/2022] Open
Abstract
Background Cardiovascular diseases are associated with growing public and private expenditure on healthcare regardless geographic region. Therefore, it is necessary to accurately estimate the overall societal costs-both direct and indirect expenses from the perspective of patients, caregivers and employers. Research Design The aim of this paper is to determine the direct and indirect costs related to cardiovascular diseases in Poland from 2015 to 2017. All costs are estimated based on data available in the public domain and obtained from the major Polish institutions. Indirect costs were calculated using a modified human capital approach. Results The financial burden of cardiovascular diseases in Poland is significant. This study revealed that total costs (direct and indirect) of cardiovascular diseases, for 2015-2017, range from 34.9 bn PLN (8.2 bn EUR) to over 40.9 bn PLN (9.6 bn EUR). Total direct cost and indirect costs were approximately 6.1 bn PLN (1.4 bn EUR) (16%) and 31.3 bn PLN (7.3 bn EUR) (84%), respectively. Conclusion Collectively, the estimated direct and indirect cost of cardiovascular diseases provide a useful input for economic impact assessments of public health programs and health technology analyses.
Collapse
Affiliation(s)
- Aneta Mela
- Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology (CePT), Medical University of Warsaw, Warsaw, Poland
| | - Elżbieta Rdzanek
- Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology (CePT), Medical University of Warsaw, Warsaw, Poland
| | - Łukasz A Poniatowski
- Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology (CePT), Medical University of Warsaw, Warsaw, Poland.,Department of Neurosurgery, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
| | - Janusz Jaroszyński
- Chair of Administrative Procedure, Faculty of Law and Administration, Maria Curie-Skłodowska University of Lublin, Lublin, Poland
| | | | - Małgorzata Gałązka-Sobotka
- Department of Management and Marketing, Faculty of Economics and Management, Łazarski University, Warsaw, Poland.,Institute of Management in Health Care, Łazarski University, Warsaw, Poland
| | - Dominik Olejniczak
- Department of Public Health, Faculty of Health Sciences, Medical University of Warsaw, Warsaw, Poland
| | - Maciej Niewada
- Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology (CePT), Medical University of Warsaw, Warsaw, Poland
| | - Anna Staniszewska
- Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology (CePT), Medical University of Warsaw, Warsaw, Poland
| |
Collapse
|
25
|
Mela A, Poniatowski ŁA, Drop B, Furtak-Niczyporuk M, Jaroszyński J, Wrona W, Staniszewska A, Dąbrowski J, Czajka A, Jagielska B, Wojciechowska M, Niewada M. Overview and Analysis of the Cost of Drug Programs in Poland: Public Payer Expenditures and Coverage of Cancer and Non-Neoplastic Diseases Related Drug Therapies from 2015-2018 Years. Front Pharmacol 2020; 11:1123. [PMID: 32922285 PMCID: PMC7456857 DOI: 10.3389/fphar.2020.01123] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2020] [Accepted: 07/10/2020] [Indexed: 11/17/2022] Open
Abstract
Background In Poland drug programmes developed by the Minister of Health and financed by the National Health Fund are special reimbursement frameworks of innovative, expensive, and mostly hospital based medical products used for a small number of patients. Research Design The research presented in this paper is based on data analysis published by the National Health Fund in Poland. The analysis focused on estimating public payer expenditure on drugs available within drug programmes from 2015 to 2018. Results In subsequent years, reimbursement of drugs used within drug programmes was associated with the National Health Fund budget expenditure of 635 mln USD, 755 mln USD, 854 mln USD, and 921 mln USD, respectively. Reimbursement of oncology drug programmes constituted 48.1%, 42.5%, 47.1%, and 52.4% and were approximately 305, 312, 402, 483 mln USD, whereas values of non-oncology drug programmes were approximately 330, 434, 452, and 438 mln USD which constituted 51.9%, 57.5%, 52.9%, and 47.6% respectively. Conclusion Despite the fact that the expenditure on drug programs in Poland are increasing every year, they undoubtedly improve the patient’s access to the most innovative oncological and nononcological therapies in the Polish healthcare system.
Collapse
Affiliation(s)
- Aneta Mela
- Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology (CePT), Medical University of Warsaw, Warsaw, Poland
| | - Łukasz A Poniatowski
- Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology (CePT), Medical University of Warsaw, Warsaw, Poland.,Department of Neurosurgery, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
| | - Bartłomiej Drop
- Department of Information Technology and Medical Statistics, Faculty of Health Sciences, Medical University of Lublin, Lublin, Poland
| | | | - Janusz Jaroszyński
- Chair of Administrative Procedure, Faculty of Law and Administration, Maria Curie-Skłodowska University of Lublin, Lublin, Poland
| | | | - Anna Staniszewska
- Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology (CePT), Medical University of Warsaw, Warsaw, Poland
| | - Jan Dąbrowski
- Department of Pharmacology, National Medicines Institute, Warsaw, Poland
| | - Anna Czajka
- Department of Neurology, Czerniakowski Hospital, Warsaw, Poland
| | - Beata Jagielska
- Department of Oncological Diagnostics, Cardiooncology and Palliative Medicine, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
| | - Monika Wojciechowska
- Department of Pediatric Nephrology, Medical University of Lublin, Lublin, Poland
| | - Maciej Niewada
- Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology (CePT), Medical University of Warsaw, Warsaw, Poland
| |
Collapse
|
26
|
Staniszewska A, Armenia J, King M, Michaloglou C, Singh M, Martin MS, Wilson Z, Proia T, Delpuech O, O'Connor M, Leo E, Valge-Archer V. Abstract 967: Anti-tumor and immune effects of olaparib +/- anti-PD-L1 in preclinical BRCA1mut tumor models. Cancer Res 2020. [DOI: 10.1158/1538-7445.am2020-967] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
PARP inhibitor treatments are synthetically lethal with BRCA1/2 mutations and, in this setting, accumulation of DNA damage leads ultimately to cell death. Increases in DNA damage are also associated with increased levels of cytosolic DNA and consequently signalling through the cGAS-STING pathway, which can lead to increased inflammatory gene expression and Type I interferon response.
We sought to evaluate the benefit of combining the PARP inhibitor olaparib with immune checkpoint blockade (ICB) in a mouse syngeneic ovarian model, BR5, which lacks BRCA1. We show that olaparib combination with anti-PD-L1 prolonged duration of anti-tumor response vs. either monotherapy. The combination increased durable complete responses (CRs) with 6/10 animals tumor free at 77 days, compared with 1/9 and 2/9 tumor-free animals for olaparib and anti-PD-L1 monotherapies, respectively. Similar results were observed for combination of olaparib with anti-CTLA-4. Furthermore, mice treated with olaparib + ICB demonstrated immunological memory, with 100% of mice with CRs successfully rejecting tumor growth upon rechallenge with BR5. Olaparib treatment of human T cells in vitro and mouse T cells in vitro and in vivo did not show inhibition of T cell activation or proliferation. Moreover, olaparib treatment led to changes in tumor immune infiltrate in the BR5 tumors, including approximately 2-fold increased CD8 T cells and 1.5-fold increased NK cells relative to vehicle.
Differential gene expression analysis of olaparib or anti-PD-L1treated BR5 tumors revealed broad upregulation of immune pathways. Interestingly, type I IFN and STING pathways showed a more pronounced upregulation with Olaparib than with anti-PD-L1 treatment. Moreover, a dose-dependent upregulation of immune pathways, including JAK-STAT, STING and type I IFN was observed in a tumor cell-centric analysis from a BRCA1mut breast PDX model treated with olaparib. In contrast, no significant upregulation of STING or type I IFN pathways is observed in response to olaparib in a BRCAwt breast PDX model.
In vitro mechanistic studies demonstrated that co-culture of olaparib-treated human BRCA1mut MDA-MB-436 tumor cells with human dendritic cells (DC) resulted in an approximately 2-fold upregulation of CD86 expression on DCs. Comparison of isogenic DLD-1 tumor cells showed CD86 upregulation on DCs only following co-culture with olaparib-treated BRCA2-/- DLD-1 cells, but not wt DLD-1 cells. Similarly, increased PD-L1 expression was only observed in BRCA2-/- DLD-1 cells treated with olaparib and following co-culture with DC. These observations suggest a basis for increased immune priming following olaparib treatment of BRCAmut tumors, which can be consolidated with ICB, such as anti-PD-L1, treatment.
Citation Format: Anna Staniszewska, Joshua Armenia, Matthew King, Chrysiis Michaloglou, Maneesh Singh, Maryann San Martin, Zena Wilson, Theresa Proia, Oona Delpuech, Mark O'Connor, Elisabetta Leo, Viia Valge-Archer. Anti-tumor and immune effects of olaparib +/- anti-PD-L1 in preclinical BRCA1mut tumor models [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 967.
Collapse
|
27
|
Śliż D, Marcinkiewicz A, Olejniczak D, Jankowski P, Staniszewska A, Mamcarz A, Walusiak-Skorupa J. Hypercholesterolemia and prevention of cardiovascular diseases in the light of preventive medical examinations of employees in Poland. Int J Occup Med Environ Health 2019; 32:865-872. [DOI: 10.13075/ijomeh.1896.01446] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
28
|
Milewska M, Grabarczyk K, Dąbrowska-Bender M, Jamróz B, Dziewulska D, Staniszewska A, Panczyk M, Szostak-Węgierek D. The prevalence and types of oral- and pharyngeal-stage dysphagia in patients with demyelinating diseases based on subjective assessment by the study subjects. Mult Scler Relat Disord 2019; 37:101484. [PMID: 31704547 DOI: 10.1016/j.msard.2019.101484] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2019] [Revised: 10/18/2019] [Accepted: 10/28/2019] [Indexed: 10/25/2022]
Abstract
BACKGROUND Studies show that dysphagia is a common problem in patients with demyelinating diseases. However, there are no published studies on dysphagia in this group of patients, which would include the individual phases or the safety and effectiveness of the swallowing process. OBJECTIVE The main objective of this study was to assess the prevalence of swallowing disorders and to characterize them based on subjective assessment by the study subjects with multiple sclerosis and Devic's syndrome. METHOD The study included 72 patients (47 F, 25 M). Patients at risk of dysphagia were identified using the DYMUS, EAT-10 and SDQ questionnaires. To assess the type of oral- and pharyngeal-stage dysphagia, questions in the questionnaires were classified into groups according to symptoms typical of each stage. RESULTS The risk of dysphagia and the need for instrumental examination were identified in 37.5% of the study subjects. Pharyngeal-stage dysphagia (repeated swallowing, increased effort of swallowing, cough, a feeling of food sticking in the throat) was reported to occur at a significantly higher frequency. However, no differences were found between difficulty in swallowing liquids and difficulty in swallowing solid food. CONCLUSION There is a need for further research, which should include a detailed dysphagia-oriented diagnosis, with a view to gaining a detailed insight into the pathophysiology of deglutition in this group of patients.
Collapse
Affiliation(s)
| | | | | | - Barbara Jamróz
- Department of Otolaryngology, Medical University of Warsaw, Poland
| | | | - Anna Staniszewska
- Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Banacha 1b, 02-097 Warsaw, Poland.
| | - Mariusz Panczyk
- Department of Education and Research in Health Sciences, Medical University of Warsaw
| | | |
Collapse
|
29
|
Lasota D, Pawłowski W, Krajewski P, Staniszewska A, Goniewicz K, Goniewicz M. Seasonality of Suicides among Victims Who Are under the Influence of Alcohol. Int J Environ Res Public Health 2019; 16:ijerph16152806. [PMID: 31390817 PMCID: PMC6696555 DOI: 10.3390/ijerph16152806] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 07/16/2019] [Revised: 08/02/2019] [Accepted: 08/05/2019] [Indexed: 02/02/2023]
Abstract
Introduction: Suicide is one of the most frequent causes of death. According to the World Health Organization (WHO), each year, over eight hundred thousand people worldwide die as a result of suicide. The most common risk factors for suicide are depressive disorders and alcohol dependence. Alcohol can directly influence a decision about suicide, or be a factor facilitating this decision. The aim of the study was to analyse the seasonality of suicides among persons under the influence of alcohol. Material and Methods: Data for analysis were obtained from the Department of Forensic Medicine (DFM) of the Medical University of Warsaw. A retrospective analysis was performed on 317 victims of suicides by hanging, those which were entered into the registry of deaths kept by the DFM in the years 2009–2013. The analysis took into account the age and sex of victims, initial cause of death, date of post-mortem examination, autopsy result and alcohol concentration in the blood or muscles of the victims. Statistical analysis was performed using IBM SPSS Statistics version 20. Results: In the analysis, a spring peak of suicides was found for men, and an autumn peak was revealed for women. In addition, a significant correlation was observed between the age of victims and the concentration of alcohol; the older the victims, the higher the alcohol concentration. However, this correlation was reported only in the spring months. Conclusions: The results of the analysis seem to be consistent with seasonal patterns observed in other studies, and they indicate the occurrence of suicide seasonality. In order to improve the strategies of suicide prevention, it is necessary to identify factors which are related to the seasonal variation of suicidal behaviours, as well as to gain knowledge about the mechanisms behind this phenomenon.
Collapse
Affiliation(s)
- Dorota Lasota
- Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Banacha 1b Street, 02097 Warsaw, Poland.
| | - Witold Pawłowski
- Department of Disaster Medicine, Medical University of Warsaw, Żwirki i Wigury 61 Street, 02091 Warsaw, Poland
| | - Paweł Krajewski
- Department of Forensic Medicine, Medical University of Warsaw, Oczki 1 Street, 00001 Warsaw, Poland
| | - Anna Staniszewska
- Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Banacha 1b Street, 02097 Warsaw, Poland
| | - Krzysztof Goniewicz
- Department of Security Studies, Polish Air Force Academy, Dywizjonu 303 35 Street, 08521 Dęblin, Poland
| | - Mariusz Goniewicz
- Department of Emergency Medicine, Medical University of Lublin, Staszica 4-6 Street, 20081 Lublin, Poland
| |
Collapse
|
30
|
Davies M, Jongh JD, Dean E, Fok JH, Goldberg FW, James N, Karmokar A, Ramos-Montoya A, Staniszewska A, Sykes A, Steeg TV, Cadogan E. Abstract 3511: Exploration of pre-clinical relationships between pharmacokinetics, pharmacodynamics and tumor volume for the novel DNA-PK inhibitor AZD7648. Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-3511] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
AZD7648 is a potent and highly selective inhibitor of DNA-dependent protein kinase (DNA-PK) that has been nominated for clinical development. DNA-PK is a nuclear serine/threonine protein kinase complex involved in DNA damage repair, and a key component of the non-homologous end joining repair mechanism of double strand breaks (DSBs). This work aimed to explore the relationships between pharmacokinetics (PK), pharmacodynamics (PD) and xenograft tumor volume from pre-clinical studies, in order to define PD requirements for pre-clinical efficacy, and to estimate a target clinical dose for AZD7648 in combination with DSB-inducing agents such as olaparib or pegylated liposomal doxorubicin (PLD). A population-based modelling approach was used to explore the PK of AZD7648 in mice. The PK model was developed using data from full PK profiles (multiple longitudinal samples per mouse), and validated against terminal sample PK data. The potential influences of strain-dependence, time non-linearity, and interaction with olaparib on the pharmacokinetics of AZD7648 were investigated. Direct and indirect inhibition PD models were fitted to the responses of biomarkers describing target engagement (pDNA-PK) or proximal downstream effects (pRPA32 (S4/8) and γH2AX). A compartmental model accurately described AZD7648 PK in mice, with rapid absorption, dose-proportional PK across the range of doses tested, time-independent parameters and no effect of olaparib co-dosing on AZD7648 PK. The PD of proximal target engagement biomarkers were best described with an Imax model with very rapid turnover (<10 minutes), which showed there was negligible delay (due to tumor distribution or pharmacology) and effectively a direct relationship between systemic PK and xenograft biomarker inhibition. Across a number of FaDu ATM KO and BT474c xenograft tumor studies, the duration of cover over IC90 correlated with efficacy in combination with olaparib or PLD, demonstrating the importance of inhibiting DNA-PK for an extended duration in each dosing period. This result was applied to define a target level and duration of PD inhibition, and, when combined with predicted human PK behaviour, a target clinical dose for AZD7648 in combination with DSB-inducing agents to inform the clinical investigation of AZD7648.
Citation Format: Michael Davies, Joost de Jongh, Emma Dean, Jacquelline H. Fok, Frederick W. Goldberg, Neil James, Ankur Karmokar, Antonio Ramos-Montoya, Anna Staniszewska, Andy Sykes, Tamara van Steeg, Elaine Cadogan. Exploration of pre-clinical relationships between pharmacokinetics, pharmacodynamics and tumor volume for the novel DNA-PK inhibitor AZD7648 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3511.
Collapse
Affiliation(s)
- Michael Davies
- 1DMPK, Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom
| | | | - Emma Dean
- 3TMU, Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom
| | - Jacquelline H. Fok
- 4Bioscience, Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom
| | - Frederick W. Goldberg
- 5Medicinal Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom
| | - Neil James
- 4Bioscience, Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom
| | - Ankur Karmokar
- 4Bioscience, Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom
| | | | - Anna Staniszewska
- 4Bioscience, Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom
| | - Andy Sykes
- 1DMPK, Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom
| | | | - Elaine Cadogan
- 4Bioscience, Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom
| |
Collapse
|
31
|
Ramos-Montoya A, Fok JH, James N, Follia V, Vazquez-Chantada M, Wijnhoven P, O’Connor LO, Karmokar A, Staniszewska A, Dean E, Hollingsworth SJ, Davies B, Cadogan EB. Abstract 3506: AZD7648, a potent and selective inhibitor of DNA-PK, potentiates activity of the PARP inhibitor olaparib resulting in sustained anti-tumour activity in xenograft and PDX models. Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-3506] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
DNA-dependent kinase (DNA-PK) is a nuclear serine/threonine protein kinase complex and a key component of the non-homologous end joining (NHEJ) process. DNA-PK plays an important role in the cellular response to DNA damage through the detection and repair of double strand breaks (DSB). DSB can be induced by a range of agents, including chemotherapy and radiation. The PARP inhibitor olaparib has also been shown to induce DSB as a consequence of trapping PARP proteins at sites of damaged DNA. Therefore, we hypothesised that DNA-PK inhibitors may combine therapeutically with PARP inhibitors. AZD7648 is a highly potent and selective inhibitor of DNA-PK (pDNA-PK cell IC50 = 92 nM) The combination treatment of AZD7648 with olaparib for 10 - 12 days in vitro leads to at least 20% greater cell growth inhibition compared with either agents as monotherapies in a panel of cell lines with deficiencies in the ATM pathway (e.g. cells lacking ATM protein or where ATM substrates are not phosphorylated after exposure to DSB inducing agents). This effect is also seen in isogenic ATM knock-out (KO) FaDu head and neck and A549 non-small cell lung cancer cell lines. At concentrations of AZD7648 (0.6 - 2 µM) and olaparib (1 µM) that have monotherapy activity in the ATM KO cells but not in their wild-type counterparts (WT), the combination treatment enhanced the G2/M cell cycle arrest caused by olaparib and led to greater levels of micronuclei formation as detected using high-content immunofluorescece assays (mean per cell: FaDu WT = 0.1, FaDu ATM KO = 0.4). This was associated with a larger quantity of chromosomal aberrations in the ATM KO versus WT cells following combination treatment detected by metaphase spread analysis (mean per cell: FaDu ATM KO = 5.5, FaDu WT = 1.2). The same phenotype was observed in A549 ATM KO versus WT cell lines. In vivo, continuous dosing of AZD7648 (75 mg/kg bid) in combination with olaparib (100 mg/kg qd) inhibited the growth of FaDu WT tumours by ~60%. However, in the FaDu ATM KO tumours complete regressions were seen after 70 days of dosing and no re-growth was detected up to 220 days later. Additionally, in PDX models of breast, lung, ovarian and head and neck cancer this combination showed tumour growth inhibition (50-100%) in 13 models and regression in 5 models, only one of these five models being ATM pathway deficient. These data confirm that DNA-PK inhibition using AZD7648 enhances the efficacy of olaparib in vitro and in vivo, providing a clear rationale for its clinical investigation.
Citation Format: Antonio Ramos-Montoya, Jacqueline H. Fok, Neil James, Valeria Follia, Mercedes Vazquez-Chantada, Paul Wijnhoven, Lenka Oplustil O’Connor, Ankur Karmokar, Anna Staniszewska, Emma Dean, Simon J. Hollingsworth, Barry Davies, Elaine B. Cadogan. AZD7648, a potent and selective inhibitor of DNA-PK, potentiates activity of the PARP inhibitor olaparib resulting in sustained anti-tumour activity in xenograft and PDX models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3506.
Collapse
Affiliation(s)
| | - Jacqueline H. Fok
- 1Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, UK, Cambridge, United Kingdom
| | - Neil James
- 1Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, UK, Cambridge, United Kingdom
| | - Valeria Follia
- 1Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, UK, Cambridge, United Kingdom
| | | | - Paul Wijnhoven
- 1Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, UK, Cambridge, United Kingdom
| | | | - Ankur Karmokar
- 1Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, UK, Cambridge, United Kingdom
| | - Anna Staniszewska
- 1Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, UK, Cambridge, United Kingdom
| | - Emma Dean
- 3TMU, IMED Biotech Unit AstraZeneca, Cambridge, UK, Cambridge, United Kingdom
| | | | - Barry Davies
- 1Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, UK, Cambridge, United Kingdom
| | - Elaine B. Cadogan
- 1Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, UK, Cambridge, United Kingdom
| |
Collapse
|
32
|
Fok JH, Ramos-Montoya A, James N, Vazquez-Chantada M, Follia V, Karmokar A, Staniszewska A, O’Connor LO, Dean E, Hollingsworth SJ, Davies BR, Cadogan EB. Abstract 3512: AZD7648, a potent and selective inhibitor of DNA-PK, potentiates the activity of ionising radiation and doxorubicin in vitro and causes tumour regression in xenograft models. Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-3512] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
DNA-dependent kinase (DNA-PK) is a nuclear serine/threonine protein kinase complex that is a key component of the non-homologous end joining (NHEJ) process. DNA-PK plays an important role in the cellular response to DNA damage through the detection and repair of DNA double strand breaks (DSB). Cancer therapies such as ionising radiation (IR) or topoisomerase II inhibitors (doxorubicin) generate DSB which can be repaired by homologous recombination (HR) or non-homologous end-joining (NHEJ). It can therefore be hypothesised a DNA-PK inhibitor would potentiate the activity of these agents. We have developed a highly potent and selective inhibitor of DNA-PK, AZD7648, which inhibits IR-induced DNA-PK S2056 auto phosphoryalation with an IC50 = 92 nM in A549 non-small cell lung cancer (NSCLC) cells. AZD7648 is a potent radiosensitiser where treatment in combination with IR led to a concentration-dependent reduction of the colony survival capacity of A549 and H1299 NSCLC cells (DEF37 at 100 nM = 1.7 and 2.5, respectively). In A549 cells, AZD7648 (≥1 µM) in combination with 2Gy IR for 48 hours led to a significant accumulation of cells arrested in the G2/M of the cell cycle, a 4-fold increase in micronuclei formation, and 3-fold induction of γH2AX, pATM S1981 and 53BP1 foci formation compared with IR alone. AZD7648 was also found to combine synergistically with doxorubicin in a panel of ovarian and triple negative breast cancer (TNBC) cell lines in cell growth inhibition assays when applying the Loewe additivity model (synergy scores 4 - 35). In vivo the combination of AZD7648 with IR (5x 2Gy) induced tumour regression in H1299 and A549 NSCLC xenografts in a dose-dependent manner (84 and 11% regression respectively), while monotherapy treatment only achieved tumour growth inhibition. In these two models the increased activation by IR of three primary DNA-PK pharmacodynamic markers, pDNAPK (S2056), pRPA32 (S4/8) and γH2AX, was inhibited by AZD7648 treatment (70-90% inhibition 2 h after IR + AZD7648). Similarly, liposomal doxorubicin (2.5 mg/kg weekly) in combination with AZD7648 (37.5 mg/kg bid) induced tumour regressions in the BT474c ER+ breast cancer xenograft model and in a TNBC PDX model (63% and 33% regression respectively), while monotherapy treatments only achieved tumour growth inhibition. These data confirm that DNA-PK inhibition with AZD7648 enhances the efficacy of a range of DSB inducing agents in vitro and in vivo, providing a clear rationale for its clinical investigation.
Citation Format: Jacqueline H. Fok, Antonio Ramos-Montoya, Neil James, Mercedes Vazquez-Chantada, Valeria Follia, Ankur Karmokar, Anna Staniszewska, Lenka Oplustil O’Connor, Emma Dean, Simon J. Hollingsworth, Barry R. Davies, Elaine B. Cadogan. AZD7648, a potent and selective inhibitor of DNA-PK, potentiates the activity of ionising radiation and doxorubicin in vitro and causes tumour regression in xenograft models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3512.
Collapse
Affiliation(s)
- Jacqueline H. Fok
- 1Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom
| | | | - Neil James
- 1Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom
| | | | - Valeria Follia
- 1Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom
| | - Ankur Karmokar
- 1Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom
| | - Anna Staniszewska
- 1Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom
| | | | - Emma Dean
- 3IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom
| | | | - Barry R. Davies
- 1Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom
| | - Elaine B. Cadogan
- 1Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom
| |
Collapse
|
33
|
Furtak-Niczyporuk M, Jaroszyński J, Mela A, Staniszewska A, Piotrowska J, Zimmermann A, Czajka-Bełz A, Dreher P, Dąbrowski J, Kapka-Skrzypczak L. [Cytostatic and cytotoxic waste - rules of conduct in Poland]. Med Pr 2019; 70:377-391. [PMID: 31110397 DOI: 10.13075/mp.5893.00827] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
Abstract
Poland is one of the European countries with the highest level of production of dangerous medical waste. Although in Europe the volume of produced cytotoxic and cytostatic waste (used in chemotherapy by oncological patients) has been declining for several years, in Poland a reverse trend has been observed. As this waste puts the safety of medical workers and patients at risk, special handling procedures are required to limit the harmful effect of these drugs on human health. In view of the above, the aim of the work was to present the rules of conduct with cytotoxic and cytostatic drugs, and their waste, in Poland. Med Pr. 2019;70(3):377-91.
Collapse
Affiliation(s)
- Marzena Furtak-Niczyporuk
- Uniwersytet Medyczny w Lublinie / Medical University of Lublin, Lublin, Poland (Katedra i Zakład Zdrowia Publicznego / Department of Public Health).
| | - Janusz Jaroszyński
- Uniwersytet Marii Curie-Skłodowskiej w Lublinie / Maria Curie-Sklodowska University of Lublin, Lublin, Poland (Wydział Prawa i Administracji, Katedra Postępowania Administracyjnego / Faculty of Law and Administration, Department of Administrative Procedure).
| | - Aneta Mela
- Warszawski Uniwersytet Medyczny / Medical University of Warsaw, Warsaw, Poland (Katedra i Zakład Farmakologii Doświadczalnej i Klinicznej / Department of Experimental and Clinical Pharmacology).
| | - Anna Staniszewska
- Warszawski Uniwersytet Medyczny / Medical University of Warsaw, Warsaw, Poland (Katedra i Zakład Farmakologii Doświadczalnej i Klinicznej / Department of Experimental and Clinical Pharmacology).
| | - Jowita Piotrowska
- Wojewódzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Łodzi / Copernicus Provincial Multidisciplinary Centre of Oncology and Traumatology in Lodz, Łódź, Poland.
| | - Agnieszka Zimmermann
- Uniwersytet Medyczny w Gdańsku / Medical University of Gdansk, Gdańsk, Poland (Zakład Prawa Medycznego i Farmaceutycznego / Department of Medical and Pharmacy Law).
| | - Anna Czajka-Bełz
- Centralny Szpital Kliniczny Ministerstwa Spraw Wewnętrznych i Administracji w Warszawie / Central Clinical Hospital of Ministry of the Interior and Administration in Warsaw, Warsaw, Poland (Klinika Neurologii / Clinical Department of Neurology).
| | - Piotr Dreher
- Uniwersytet Medyczny w Lublinie / Medical University of Lublin, Lublin, Poland (Katedra i Zakład Zdrowia Publicznego / Department of Public Health).
| | - Jan Dąbrowski
- Instytut Medycyny Doświadczalnej i Klinicznej. im. M. Mossakowskiego Polskiej Akademii Nauk / Mossakowski Medical Research Centre Polish Academy of Sciences, Warsaw, Poland (Zakład Fizjologii Stosowanej / Department of Applied Physiology).
| | - Lucyna Kapka-Skrzypczak
- Instytut Medycyny Wsi im. Witolda Chodźki w Lublinie / Witold Chodźko Institute of Rural Health in Lublin, Lublin, Poland (Zakład Biologii Medycznej i Badań Translacyjnych / Department of Molecular Biology and Translational Research)
| |
Collapse
|
34
|
Juszczyk G, Czerw AI, Religioni U, Olejniczak D, Walusiak-Skorupa J, Banas T, Mikos M, Staniszewska A. Work Ability Index (WAI) values in a sample of the working population in Poland. Ann Agric Environ Med 2019; 26:78-84. [PMID: 30922034 DOI: 10.26444/aaem/91471] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
INTRODUCTION Ability to work is most often defined as a relationship between a person's resources and requirements specific to a particular type of work. It is the result of interaction between job requirements in terms of physical and mental strain, capabilities and skills of the employee, as well as his/her health condition and own evaluation of functioning in a given organizational and social situation. OBJECTIVE The primary objective of the study was to evaluate the current value of the Work Ability Index (WAI) in a sample of employees in Poland. MATERIAL AND METHODS The study sample was selected purposefully from 422,000 employees covered by the largest occupational health provider in Poland. The standard WAI questionnaire provided by CAWI (Computer-Assisted Web Interview) methodology was voluntary and completed anonymously by 688 employees within 12 months (0.16% response rate). The results were statistically analyzed using the Pearson's chi-squared test and correlation coefficient, independent-sample T test and one-way analysis of variance (p<0.05). RESULTS It was found that the average value of WAI was 37.5 ± 7.7, and 37% of the participants represented low to moderate ability to work. The results showed no significant correlation between the WAI value and its 7 compounds and demographic variables. Nonetheless, a dependency between WAI level and industrial branch was observed. CONCLUSIONS Subjects with moderate and low WAI (1/3 of the study population) had particular indications to implement prophylactic actions, especially for the health care employees and civil servants, whose ability to work may be subject to accelerated deterioration.
Collapse
Affiliation(s)
- Grzegorz Juszczyk
- Department of Public Health, Medical University of Warsaw, Warsaw, Poland.
| | | | - Urszula Religioni
- Collegium od Business Administration, Warsaw School of Economics, Warsaw, Poland.
| | - Dominik Olejniczak
- Department of Public Health, Medical University of Warsaw, Warsaw, Poland.
| | - Jolanta Walusiak-Skorupa
- Department of Occupational Diseases and Toxicology Clinic, Institute of Occupational Medicine, Lodz, Poland.
| | - Tomasz Banas
- Department of Gynaecology and Oncology, Jagiellonian University Medical College, Krakow, Poland.
| | - Marcin Mikos
- Institute of Public Health, Jagiellonian University Medical College, Krakow, Poland.
| | - Anna Staniszewska
- Department of Experimental and Clinical Pharmacology, Medical University, Warsaw, Poland.
| |
Collapse
|
35
|
Tatarkiewicz J, Rzodkiewicz P, Żochowska M, Staniszewska A, Bujalska-Zadrożny M. New antihistamines - perspectives in the treatment of some allergic and inflammatory disorders. Arch Med Sci 2019; 15:537-553. [PMID: 30899308 PMCID: PMC6425212 DOI: 10.5114/aoms.2017.68534] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/06/2016] [Accepted: 03/13/2017] [Indexed: 12/29/2022] Open
Affiliation(s)
- Jan Tatarkiewicz
- Department of Pharmacodynamics, Centre for Preclinical Research and Technology, Medical University of Warsaw, Warsaw, Poland
| | - Przemysław Rzodkiewicz
- Department of Biochemistry and Molecular Biology, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland
- Department of General and Experimental Pathology, Medical University of Warsaw, Warsaw, Poland
| | - Małgorzata Żochowska
- Department of Pharmacodynamics, Centre for Preclinical Research and Technology, Medical University of Warsaw, Warsaw, Poland
| | - Anna Staniszewska
- Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland
| | - Magdalena Bujalska-Zadrożny
- Department of Pharmacodynamics, Centre for Preclinical Research and Technology, Medical University of Warsaw, Warsaw, Poland
| |
Collapse
|
36
|
Carnevalli LS, Sinclair C, Taylor MA, Gutierrez PM, Langdon S, Coenen-Stass AML, Mooney L, Hughes A, Jarvis L, Staniszewska A, Crafter C, Sidders B, Hardaker E, Hudson K, Barry ST. PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8 + T-cell activity. J Immunother Cancer 2018; 6:158. [PMID: 30587236 PMCID: PMC6307194 DOI: 10.1186/s40425-018-0457-0] [Citation(s) in RCA: 57] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2018] [Accepted: 11/20/2018] [Indexed: 01/08/2023] Open
Abstract
PI3K inhibitors with differential selectivity to distinct PI3K isoforms have been tested extensively in clinical trials, largely to target tumor epithelial cells. PI3K signaling also regulates the immune system and inhibition of PI3Kδ modulate the tumor immune microenvironment of pre-clinical mouse tumor models by relieving T-regs-mediated immunosuppression. PI3K inhibitors as a class and PI3Kδ specifically are associated with immune-related side effects. However, the impact of mixed PI3K inhibitors in tumor immunology is under-explored. Here we examine the differential effects of AZD8835, a dual PI3Kα/δ inhibitor, specifically on the tumor immune microenvironment using syngeneic models. Continuous suppression of PI3Kα/δ was not required for anti-tumor activity, as tumor growth inhibition was potentiated by an intermittent dosing/schedule in vivo. Moreover, PI3Kα/δ inhibition delivered strong single agent anti-tumor activity, which was associated with dynamic suppression of T-regs, improved CD8+ T-cell activation and memory in mouse syngeneic tumor models. Strikingly, AZD8835 promoted robust CD8+ T-cell activation dissociated from its effect on T-regs. This was associated with enhancing effector cell viability/function. Together these data reveal novel mechanisms by which PI3Kα/δ inhibitors interact with the immune system and validate the clinical compound AZD8835 as a novel immunoncology drug, independent of effects on tumor cells. These data support further clinical investigation of PI3K pathway inhibitors as immuno-oncology agents.
Collapse
Affiliation(s)
- Larissa S Carnevalli
- Bioscience, Oncology, IMED Biotech Unit AstraZeneca, Francis Crick Ave, Cambridge, CB2 0SL, UK.
| | - Charles Sinclair
- Bioscience, Oncology, IMED Biotech Unit AstraZeneca, Francis Crick Ave, Cambridge, CB2 0SL, UK
| | - Molly A Taylor
- Bioscience, Oncology, IMED Biotech Unit AstraZeneca, Francis Crick Ave, Cambridge, CB2 0SL, UK
| | | | - Sophie Langdon
- Bioscience, Oncology, IMED Biotech Unit AstraZeneca, Francis Crick Ave, Cambridge, CB2 0SL, UK.,Present Address: University of Birmingham, B15 2TT, Birmingham, UK
| | - Anna M L Coenen-Stass
- Bioscience, Oncology, IMED Biotech Unit AstraZeneca, Francis Crick Ave, Cambridge, CB2 0SL, UK
| | - Lorraine Mooney
- Bioscience, Oncology, IMED Biotech Unit AstraZeneca, Alderley Park, Alderley Edge, Macclesfield, SK10 4TG, UK.,Present Address: Alderley Park Limited, Preclinical Services, Alderley Park, Macclesfield, SK10 4TG, UK
| | - Adina Hughes
- Bioscience, Oncology, IMED Biotech Unit AstraZeneca, Francis Crick Ave, Cambridge, CB2 0SL, UK
| | - Laura Jarvis
- Bioscience, Oncology, IMED Biotech Unit AstraZeneca, Francis Crick Ave, Cambridge, CB2 0SL, UK
| | - Anna Staniszewska
- Bioscience, Oncology, IMED Biotech Unit AstraZeneca, Francis Crick Ave, Cambridge, CB2 0SL, UK
| | - Claire Crafter
- Bioscience, Oncology, IMED Biotech Unit AstraZeneca, Francis Crick Ave, Cambridge, CB2 0SL, UK
| | - Ben Sidders
- Bioscience, Oncology, IMED Biotech Unit AstraZeneca, Francis Crick Ave, Cambridge, CB2 0SL, UK
| | - Elizabeth Hardaker
- Bioscience, Oncology, IMED Biotech Unit AstraZeneca, Francis Crick Ave, Cambridge, CB2 0SL, UK
| | - Kevin Hudson
- Bioscience, Oncology, IMED Biotech Unit AstraZeneca, Alderley Park, Alderley Edge, Macclesfield, SK10 4TG, UK.,Present Address: 2theNth, Adelphi Group, Bollington, SK10 5JB, UK
| | - Simon T Barry
- Bioscience, Oncology, IMED Biotech Unit AstraZeneca, Francis Crick Ave, Cambridge, CB2 0SL, UK.
| |
Collapse
|
37
|
Mela A, Staniszewska A, Wrona W, Poniatowski ŁA, Jaroszyński J, Niewada M. The direct and indirect costs of epilepsy in Poland estimates for 2014-2016 years. Expert Rev Pharmacoecon Outcomes Res 2018; 19:353-362. [PMID: 30293466 DOI: 10.1080/14737167.2019.1533817] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
BACKGROUND According to the current data, around 1% of the Poland population have epilepsy, which comprises about 400,000 people. This group of patients requires life-long therapy including both drug therapy and hospitalization. The character of the epilepsy has a significant impact on the expenses borne by individual patients, and the prevalence of the disease has a significant impact on the health care system. METHODS This article aims to measure the direct and indirect costs of epilepsy in Poland estimates for the years 2014-2016 (top-down approach). We use a modified human capital approach and a unique dataset provided by the number of Polish institutions including National Health Fund, Social Insurance Institution, and Central Statistical Office. RESULTS Epilepsy burden in Poland is significant. In the years 2014-2016, the total direct cost of epilepsy amounted to, respectively, 355 mln PLN (84 mln EUR), 368 mln PLN (87 mln EUR), and 373 mln PLN (88 mln EUR), but the total indirect cost amounted to 1 bn PLN (239 mln EUR), 949 mln PLN (224 mln EUR), and 848 mln PLN (200 mln EUR). CONCLUSIONS Direct and indirect costs of epilepsy can be a useful input for health technology analyses of drugs or economic impact assessments of public health programs.
Collapse
Affiliation(s)
- Aneta Mela
- a Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology (CePT) , Medical University of Warsaw , Warsaw , Poland
| | - Anna Staniszewska
- a Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology (CePT) , Medical University of Warsaw , Warsaw , Poland
| | | | - Łukasz A Poniatowski
- a Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology (CePT) , Medical University of Warsaw , Warsaw , Poland.,c Department of Neurosurgery , Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology , Warsaw , Poland
| | - Janusz Jaroszyński
- d Department of Public Health, 2nd Faculty of Medicine , Medical University of Lublin , Lublin , Poland
| | - Maciej Niewada
- a Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology (CePT) , Medical University of Warsaw , Warsaw , Poland
| |
Collapse
|
38
|
Sinclair C, Revenko AS, Peter A, Johnson RB, Hettrick LA, Taylor M, Staniszewska A, Hughes A, Sandin L, Klein S, Watt A, Barry S, Monia BT, Lyne P, Macleod AR, Edbrooke M. Abstract 5561: High-affinity antisense oligonucleotides targeting Foxp3 inhibit immunosuppressive function of regulatory T-cells and produce antitumor effects in syngeneic tumor models. Cancer Res 2018. [DOI: 10.1158/1538-7445.am2018-5561] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Regulatory T-cells (Treg) contribute to cancer progression by suppressing anti-tumor immuity. Tregs specifically require expression of the lineage defining transcription factor Foxp3 for their development and function, but this protein cannot be targeted with conventional small molecule or biologic drugs. We employed next-generation antisense inhibitors (Gen 2.5 cEt-modified ASOs) in an attempt to selectively inhibit Foxp3 expression in mouse Treg cells, and evaluated consequences of ASO-mediated Foxp3 knock-down in vitro and in vivo. Mouse Foxp3-specific ASOs promoted potent dose-dependent reductions in Foxp3 mRNA and protein in vitro, without the use of transfection reagents. Foxp3 knockdown also resulted in loss of immunosuppressive markers and conferred Tregs with a reduced immunosuppressive capacity. Whilst genetic ablation of FOXP3 leads to manifestation of autoimmunity due to a complete loss of Treg function, we observed that the systemic delivery of unformulated mouse Foxp3 ASOs to WT mice resulted in Foxp3 knockdown in vivo, but spared mice from an autoimmune phenotype. Nevertheless, when syngeneic tumor-bearing mice were treated with mouse Foxp3 ASOs tumor growth was significantly attenuated, with a fraction of animals (25%-50%) achieving complete regressions. Anti-tumor activity of mouse Foxp3 ASOs was associated with immunophenotypic changes consistent with an increased anti-tumor immune response. Overall these data demonstrate the therapeutic capacity of mouse ASO to directly target regulatory T-cells, and suggesting that targeting of Foxp3 represents an attractive opportunity in cancer immunotherapy.
Citation Format: Charles Sinclair, Alexey S. Revenko, Alison Peter, Robert B. Johnson, Lisa A. Hettrick, Molly Taylor, Anna Staniszewska, Adina Hughes, Lisa Sandin, Stephanie Klein, Andrew Watt, Simon Barry, Brett T. Monia, Paul Lyne, A Robert Macleod, Mark Edbrooke. High-affinity antisense oligonucleotides targeting Foxp3 inhibit immunosuppressive function of regulatory T-cells and produce antitumor effects in syngeneic tumor models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 5561.
Collapse
|
39
|
Langdon S, Hughes A, Taylor MA, Kuczynski EA, Mele DA, Delpuech O, Jarvis L, Staniszewska A, Cosulich S, Carnevalli LS, Sinclair C. Combination of dual mTORC1/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunity. Oncoimmunology 2018; 7:e1458810. [PMID: 30221055 PMCID: PMC6136876 DOI: 10.1080/2162402x.2018.1458810] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2018] [Accepted: 03/23/2018] [Indexed: 12/02/2022] Open
Abstract
mTOR inhibition can promote or inhibit immune responses in a context dependent manner, but whether this will represent a net benefit or be contraindicated in the context of immunooncology therapies is less understood. Here, we report that the mTORC1/2 dual kinase inhibitor vistusertib (AZD2014) potentiates anti-tumour immunity in combination with anti-CTLA-4 (αCTLA-4), αPD-1 or αPD-L1 immune checkpoint blockade. Combination of vistusertib and immune checkpoint blocking antibodies led to tumour growth inhibition and improved survival of MC-38 or CT-26 pre-clinical syngeneic tumour models, whereas monotherapies were less effective. Underlying these combinatorial effects, vistusertib/immune checkpoint combinations reduced the occurrence of exhausted phenotype tumour infiltrating lymphocytes (TILs), whilst increasing frequencies of activated Th1 polarized T-cells in tumours. Vistusertib alone was shown to promote a Th1 polarizing proinflammatory cytokine profile by innate primary immune cells. Moreover, vistusertib directly enhanced activation of effector T-cell and survival, an effect that was critically dependent on inhibitor dose. Therefore, these data highlight direct, tumour-relevant immune potentiating benefits of mTOR inhibition that complement immune checkpoint blockade. Together, these data provide a clear rationale to investigate such combinations in the clinic.
Collapse
Affiliation(s)
- Sophie Langdon
- Bioscience, Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom
| | - Adina Hughes
- Bioscience, Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom
| | - Molly A Taylor
- Bioscience, Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom
| | | | - Deanna A Mele
- Bioscience, Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, USA
| | - Oona Delpuech
- Bioscience, Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom
| | - Laura Jarvis
- Bioscience, Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom
| | - Anna Staniszewska
- Bioscience, Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom
| | - Sabina Cosulich
- Bioscience, Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom
| | | | - Charles Sinclair
- Bioscience, Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom
| |
Collapse
|
40
|
Staniszewska A, Lubiejewska A, Czerw A, Dąbrowska-Bender M, Duda-Zalewska A, Olejniczak D, Juszczyk G, Bujalska-Zadrożny M. Awareness and attitudes towards clinical trials among Polish oncological patients who had never participated in a clinical trial. ADV CLIN EXP MED 2018; 27:525-529. [PMID: 29616747 DOI: 10.17219/acem/68762] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
BACKGROUND Participation in a clinical trial significantly shortens waiting time associated with receiving specialist care. Furthermore, it may be the case that, through clinical trials, subjects can access medicines that are not typically available in Poland. OBJECTIVES The aim of this study was to determine the opinions of oncological patients about clinical trials. MATERIAL AND METHODS The research has been carried out during the years 2014-2016. A proprietary questionnaire consisting of 10 closed, single and multiple choice questions about awareness and perceptions of clinical trials, and 5 questions concerning demographic information was used. A group of 256 patients with cancer (54% women, 46% men), aged 21-77 years, was surveyed. RESULTS Respondents were statistically more likely to decide to participate in a clinical trial as oncological patients than the healthy volunteers (Pearson's χ2 test p = 0.00006). The desire to qualify for clinical trials in no way depends on the knowledge of side effects (Pearson's χ2 test p = 0.16796). CONCLUSIONS Our study found that the patients' awareness about clinical trials varied. However, a positive attitude towards research was visible. The main identified barriers to clinical trial participation were fear of possible side effects. Most patients regarded clinical trials as useful, and considered that they are conducted to introduce new treatment/new drug.
Collapse
Affiliation(s)
- Anna Staniszewska
- Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Poland
| | | | - Aleksandra Czerw
- Department of Public Health, Medical University of Warsaw, Poland
| | | | | | | | | | | |
Collapse
|
41
|
Dąbrowska-Bender M, Kozaczuk A, Pączek L, Milkiewicz P, Słoniewski R, Staniszewska A. Patient Quality of Life After Liver Transplantation in Terms of Emotional Problems and the Impact of Sociodemographic Factors. Transplant Proc 2018; 50:2031-2038. [PMID: 30177104 DOI: 10.1016/j.transproceed.2018.03.113] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2017] [Revised: 03/15/2018] [Accepted: 03/23/2018] [Indexed: 12/16/2022]
Abstract
INTRODUCTION Liver transplantation is recognized as an effective and necessary treatment of chronic as well as acute hepatic failure. The assessment of quality of life (QoL) after transplantation represents an ancillary tool to evaluate the efficacy of solid organ transplantation in addition to graft and patient survival rates and complications. The global assessment of QoL after transplantation usually confirms improvement compared to pretransplant conditions. PURPOSE An attempt to evaluate the quality of life of patients after liver transplantation, with particular reference to sociodemographic factors and emotional problems. MATERIALS AND METHODS The study group included 121 patients (55 women and 66 men) at the age of 19 to 71 years who underwent surgery in the Central Teaching Hospital of the Medical University of Warsaw and the Infant Jesus Teaching Hospital in Warsaw, and were subsequently treated in an outpatient transplant clinic. The scoring procedure for the areas analyzed was based on the 36-Item Short Form Health Survey (SF-36) and the Hospital Anxiety and Depression Scale (HADS). RESULTS Higher patients age was correlated with lower quality of life of patients after liver transplantation, including physical functioning (patients >40 years of age declared lower physical performance, and patients <30 years of age indicated greatest limitations in their kind of work or other activities). The frequency of pain was also age-dependent (mostly patients >50 years of age). Women more often than men had worrying thoughts, were feeling tense or wound up, and had sudden feelings of anxiety or panic. By contrast, older people often declared that they felt to be slowed down. CONCLUSIONS To reduce pain and to improve physical performance of the study patients, rehabilitation procedures should be considered. Patients indicating symptoms associated with anxiety and depression should be referred to a clinical psychologist.
Collapse
Affiliation(s)
- M Dąbrowska-Bender
- Department of Clinical Dietetics, Medical University of Warsaw, Warsaw, Poland.
| | - A Kozaczuk
- Medical University of Warsaw, Warsaw, Poland
| | - L Pączek
- Department of Immunology, Transplant Medicine and Internal Diseases, Transplantation Institute, Medical University of Warsaw, Warsaw, Poland
| | - P Milkiewicz
- Liver and Internal Medicine Unit, Department of General, Transplant and Liver Surgery, Medical University of Warsaw, Warsaw, Poland
| | - R Słoniewski
- Department of Public Health, Medical University of Warsaw, Warsaw, Poland
| | - A Staniszewska
- Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland
| |
Collapse
|
42
|
Ross SJ, Revenko AS, Hanson LL, Ellston R, Staniszewska A, Whalley N, Pandey SK, Revill M, Rooney C, Buckett LK, Klein SK, Hudson K, Monia BP, Zinda M, Blakey DC, Lyne PD, Macleod AR. Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS. Sci Transl Med 2018; 9:9/394/eaal5253. [PMID: 28615361 DOI: 10.1126/scitranslmed.aal5253] [Citation(s) in RCA: 118] [Impact Index Per Article: 19.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2016] [Accepted: 04/21/2017] [Indexed: 12/28/2022]
Abstract
Activating mutations in KRAS underlie the pathogenesis of up to 20% of human tumors, and KRAS is one of the most frequently mutated genes in cancer. Developing therapeutics to block KRAS activity has proven difficult, and no direct inhibitor of KRAS function has entered clinical trials. We describe the preclinical evaluation of AZD4785, a high-affinity constrained ethyl-containing therapeutic antisense oligonucleotide (ASO) targeting KRAS mRNA. AZD4785 potently and selectively depleted cellular KRAS mRNA and protein, resulting in inhibition of downstream effector pathways and antiproliferative effects selectively in KRAS mutant cells. AZD4785-mediated depletion of KRAS was not associated with feedback activation of the mitogen-activated protein kinase (MAPK) pathway, which is seen with RAS-MAPK pathway inhibitors. Systemic delivery of AZD4785 to mice bearing KRAS mutant non-small cell lung cancer cell line xenografts or patient-derived xenografts resulted in inhibition of KRAS expression in tumors and antitumor activity. The safety of this approach was demonstrated in mice and monkeys with KRAS ASOs that produced robust target knockdown in a broad set of tissues without any adverse effects. Together, these data suggest that AZD4785 is an attractive therapeutic for the treatment of KRAS-driven human cancers and warrants further development.
Collapse
|
43
|
Abstract
AIM The aim of the study was the subjective assessment of the quality of life (QoL) of 140 patients treated with dialysis (peritoneal dialysis and hemodialysis). BACKGROUND Chronic kidney disease and the methods of its treatment play an important part in shaping the QoL of patients receiving dialysis. As a result, kidney failure causes many limitations in patients' physical, mental, and social activities. METHODS The instrument to measure the QoL was the authors' own questionnaire made on the basis of Kidney Disease and Quality of Life Short Form version 1.2 (KDQOL - SF 1.2) and their selection of areas influencing the perceived QoL of chronically ill patients. RESULTS The research showed that patients receiving peritoneal dialysis assessed their QoL in its different dimensions as much higher than patients receiving hemodialysis. The parameter having the biggest negative impact on the QoL of patients receiving hemodialysis was an impeded possibility to continue work or studies and a change of life plans. The will to live was more highly assessed by patients receiving peritoneal dialysis as compared to patients receiving hemodialysis. CONCLUSION In order to improve the functioning of hemodialysis patients in a manner most similar to healthy persons, the renal replacement therapy should consider patients' individual needs and expectations, ie, guarantee flexible hours of work or study and of receiving dialysis. In addition, patients treated with hemodialysis should receive psychological care, in particular those demonstrating emotional problems, in order to achieve better results in therapy and improve their QoL.
Collapse
Affiliation(s)
- Marta Dąbrowska-Bender
- Department of Clinical Dietetics, Medical University of Warsaw, Warsaw, Poland
- Correspondence: Marta Dąbrowska-Bender, Department of Clinical Dietetics, Medical University of Warsaw, ul. E. Ciołka 27, 01-445 Warsaw, Poland, Tel +48 22 57 20 931, Email
| | - Grażyna Dykowska
- Department of Public Health, Medical University of Warsaw, Warsaw, Poland
| | - Wioletta Żuk
- Department of Surgery, Transplantation and Extracorporeal Surgery, Medical University of Warsaw, Warsaw, Poland
| | - Magdalena Milewska
- Department of Clinical Dietetics, Medical University of Warsaw, Warsaw, Poland
| | - Anna Staniszewska
- Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland
| |
Collapse
|
44
|
Revenko AS, Sinclair C, Johnson B, Hettrick L, Peter A, Staniszewska A, Hughes A, Sandin L, Taylor M, Klein S, Watt A, Monia B, Edbrooke M, MacLeod AR. Abstract LB-B20: High-affinity antisense oligonucleotides targeting Foxp3 inhibit immunosuppressive function of regulatory T cells and produce anti-tumor effects in syngeneic tumor models. Mol Cancer Ther 2018. [DOI: 10.1158/1535-7163.targ-17-lb-b20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Regulatory T cells (Treg) contribute to the progression of cancer through suppression of specific anti-tumor effector immune responses. Therefore, inhibition of Treg function is an attractive approach for cancer immunotherapy. However, despite substantial effort, specific inhibition of Tregs remains a challenge. Foxp3 is a Treg-specific transcription factor required for their development and function. We employed next-generation antisense inhibitors (Gen 2.5 cEt-modified ASOs) to selectively inhibit Foxp3 expression in mouse Treg cells and evaluated consequences of ASO-mediated Foxp3 knock-down in vitro and in vivo. Mouse Foxp3-specific ASOs produced potent dose-dependent reductions in Foxp3 mRNA and protein in mouse Tregs in vitro without the use of transfection reagents. Reductions of Foxp3 in mouse Tregs was associated with loss of expression of immunosuppressive markers as well as loss of immunosuppressive function in vitro. Systemically delivered unformulated cEt-modified mouse Foxp3 ASOs reduced Foxp3 mRNA and protein in Tregs in normal mice. Importantly, this inhibition, in contrast to the phenotype of Foxp3 KO mice, was not associated with a significant autoimmune phenotype. When mouse Foxp3 ASOs were administered to syngeneic tumor-bearing mice they produced significant Foxp3 mRNA and protein knockdown in tumor-infiltrating Tregs. The growth of tumors in mouse Foxp3 ASO-treated animals was significantly attenuated with a fraction of animals (25%-50%) achieving complete regressions. Anti-tumor activity of mouse Foxp3 ASOs was associated with immunophenotype changes consistent with the increased anti-tumor immune response. Overall these data demonstrate that regulatory T cells can be effectively targeted by ASOs and that Foxp3 ASOs represent a potentially attractive therapeutic approach in cancer immunotherapy.
Citation Format: Alexey S. Revenko, Charles Sinclair, Ben Johnson, Lisa Hettrick, Alison Peter, Anna Staniszewska, Adina Hughes, Linda Sandin, Molly Taylor, Stephanie Klein, Andy Watt, Brett Monia, Mark Edbrooke, A. Robert MacLeod. High-affinity antisense oligonucleotides targeting Foxp3 inhibit immunosuppressive function of regulatory T cells and produce anti-tumor effects in syngeneic tumor models [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2017 Oct 26-30; Philadelphia, PA. Philadelphia (PA): AACR; Mol Cancer Ther 2018;17(1 Suppl):Abstract nr LB-B20.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | - Andy Watt
- 1Ionis Pharmaceuticals, Carlsbad, CA
| | | | | | | |
Collapse
|
45
|
Olejniczak D, Bugajec D, Staniszewska A, Panczyk M, Kielan A, Czerw A, Mańczuk M, Juszczyk G, Skonieczna J, Brytek-Matera A. Risk assessment of night-eating syndrome occurrence in women in Poland, considering the obesity factor in particular. Neuropsychiatr Dis Treat 2018; 14:1521-1526. [PMID: 29942130 PMCID: PMC6005332 DOI: 10.2147/ndt.s159562] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
INTRODUCTION Night-eating syndrome (NES) involves uncontrolled and most often repeated binge eating during the night. It is related with mood disorders as well as sleep disorders and it may cause obesity. Risks related to NES are obesity, binge eating disorder, bulimia nervosa, affective disorders, and sleep disorders. The objective of this study is to analyze eating habits in terms of the risk assessment of NES occurrence in the population of women in the Masovian Voivodeship (in Poland). PATIENTS AND METHODS Six hundred and eleven women living in the Masovian Voivodeship participated in the study. The average age of the respondents was 22.7 years (median = 23.0; interquartile range = 3.0). The Night Eating Questionnaire (NEQ) was used to assess the risk of NES. RESULTS In the studied group of women, 1.3% of cases (N = 12) reached a NEQ total score of ≥25, which indicates a probability of 40.7% for NES, while 0.7% (N = 4) reached a score of ≥30, which indicates a probability of 72.2% for occurrence of this syndrome. The highest average total score was observed in the group of obese people. The level of education of the participants did not significantly affect the NEQ score. A weak correlation was observed between the place of residence variable and the mood/sleep subscale (r = 0.11, P < 0.01). CONCLUSION NES may be one of the causes of overweight and obesity; therefore, the need for further studies on this health issue is justified. It is worth pointing out that knowing the conditions responsible for the occurrence of NES, it is possible to suggest a prevention procedure for this condition.
Collapse
Affiliation(s)
- Dominik Olejniczak
- Department of Public Health, Faculty of Health Science, Medical University of Warsaw, Warsaw, Poland
| | - Dorota Bugajec
- Students' Scientific Public Health Association, Health Promotion Section, Medical University of Warsaw, Warsaw, Poland
| | - Anna Staniszewska
- Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland
| | - Mariusz Panczyk
- Division of Teaching and Outcomes of Education, Faculty of Health Science, Warsaw Medical University, Warsaw, Poland
| | - Aleksandra Kielan
- Department of Public Health, Faculty of Health Science, Medical University of Warsaw, Warsaw, Poland
| | - Aleksandra Czerw
- Department of Public Health, Faculty of Health Science, Medical University of Warsaw, Warsaw, Poland
| | - Marta Mańczuk
- Department of Cancer Epidemiology and Prevention, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland
| | - Grzegorz Juszczyk
- Department of Public Health, Faculty of Health Science, Medical University of Warsaw, Warsaw, Poland
| | - Joanna Skonieczna
- Department of Public Health, Faculty of Health Science, Medical University of Warsaw, Warsaw, Poland
| | - Anna Brytek-Matera
- Katowice Faculty, SWPS University of Social Sciences and Humanities, Warsaw, Poland
| |
Collapse
|
46
|
Lynch JT, Polanska UM, Delpuech O, Hancox U, Trinidad AG, Michopoulos F, Lenaghan C, McEwen R, Bradford J, Polanski R, Ellston R, Avivar-Valderas A, Pilling J, Staniszewska A, Cumberbatch M, Critchlow SE, Cruzalegui F, Barry ST. Inhibiting PI3Kβ with AZD8186 Regulates Key Metabolic Pathways in PTEN-Null Tumors. Clin Cancer Res 2017; 23:7584-7595. [DOI: 10.1158/1078-0432.ccr-17-0676] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2017] [Revised: 08/12/2017] [Accepted: 09/26/2017] [Indexed: 11/16/2022]
|
47
|
Dąbrowska-Bender M, Słoniewski R, Religioni U, Juszczyk G, Słoniewska A, Staniszewska A. Analysis of Quality of Life Subjective Perception by Patients Treated for Prostate Cancer with the EORTC QLQ-C30 Questionnaire and QLQ-PR25 Module. J Cancer Educ 2017; 32:509-515. [PMID: 26614256 DOI: 10.1007/s13187-015-0954-5] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
Prostate cancer in men is the second most occurring cancer in Poland and represents approximately 13.2 % of all cancers. At the same time, it is the third largest cause of death in men, being responsible for approximately 8 % of deaths. The study was conducted among patients of Oncological Hospital in Wieliszew. The study included 83 men diagnosed with prostate cancer at the age of 51-84 years. The patients gave their written consent to participate in the study, to which the overall standardized questionnaires EORTC QLQ-C30 and QLQ-PR25 for patients with prostate cancer was applied. Significant deterioration of the state of health due to cancer was indicated by a total of 10.84 % of patients. At the same time, it was found that although there are differences between quality of life in various age groups of respondents, they are statistically insignificant (Chi2 = 59.96; p = 0.00734; R = 0.09; p > 0.05). Subjective QoL did not depend on the stage of cancer treatment, type of therapy, or significant deterioration in the patient's state of health in the last stage of disease. Both disease and therapy have impact on quality of life in all its dimensions, in particular as regards the patient's physical functioning and his frequent fatigue. There is a strong relationship between a patient's subjective assessment of quality of life and pain that significantly hampers everyday activities. This demonstrates the need for continuous monitoring and relieving pain directly associated with cancer and methods of its treatment.
Collapse
Affiliation(s)
- Marta Dąbrowska-Bender
- Department of Public Health, Medical University of Warsaw, Banacha 1a, Block F, 02-097, Warsaw, Poland.
| | - Robert Słoniewski
- Department of Public Health, Medical University of Warsaw, Banacha 1a, Block F, 02-097, Warsaw, Poland
| | - Urszula Religioni
- Department of Public Health, Medical University of Warsaw, Banacha 1a, Block F, 02-097, Warsaw, Poland
| | - Grzegorz Juszczyk
- Department of Public Health, Medical University of Warsaw, Banacha 1a, Block F, 02-097, Warsaw, Poland
| | - Anna Słoniewska
- Mazowiecki Oncological Hospital in Wieliszew, Warsaw, Poland
| | - Anna Staniszewska
- Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland
| |
Collapse
|
48
|
Abstract
OBJECTIVES We assessed self-medication behaviors and identified factors associated with self-treatment among adults with epilepsy. METHODS We carried out this study on 380 patients with epilepsy using an author-designed questionnaire. RESULTS Patients who took medication more than once a day were more likely to comply with times of taking medication (p = .009); people using polytherapy were more likely to forget to take their medication (p < .001). Married persons missed a dose of a drug considerably less often than other patients (p = .001). The youngest patients were the least likely to miss drug doses (p = .026). The oldest patients (p = .003) and divorced patients also were more likely to miss doses (p = .003). CONCLUSIONS Persons experiencing epilepsy should be educated on the proper use of antiepileptic drugs (AEDs); moreover, their preferences should be considered when types of therapy are prescribed. Patients who deviate from recommended use of medication should report these practices to medical personnel so that potential changes in health status can be addressed properly.
Collapse
Affiliation(s)
- Anna Staniszewska
- Medical University of Warsaw, Department of Experimental and Clinical Pharmacology, Warsaw, Poland.,
| | - Elwira Smoleńska
- Medical University of Warsaw, Department of Experimental and Clinical Pharmacology, Warsaw, Poland
| | - Urszula Religioni
- Collegium of Socio-Economics, Warsaw School of Economics, Warsaw, Poland
| |
Collapse
|
49
|
Riess J, Floch N, Martin M, Orme J, Staniszewska A, Menard L, Cuomo ME, O'Neill D, Ward R, Finlay R, McKerrecher D, Cheng M, Vang D, Tsai R, Ye C, Keck JG, Gandara DR, Mack PC, Cross D. Antitumor activity of osimertinib in NSCLC harboring EGFR exon 20 insertions. J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.15_suppl.9030] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9030 Background: EGFR exon 20 insertions (Ex20Ins), the 3rd most common EGFR activating mutation, are generally unresponsive to 1st and 2nd generation EGFR-TKIs. Development of EGFR-TKIs that effectively target NSCLC with Ex20Ins mutations represents a major unmet need. Osimertinib is an EGFR TKI approved for the treatment of advanced NSCLC harboring EGFR T790M, but the potential of osimertinib remains to be fully assessed in patients (pts) with Ex20Ins NSCLC. Methods: CRISPR engineered Ex20Ins cell line xenografts representing the two most common Ex20Ins (D770_N771InsSVD and V769_D770InsASV) and pt derived xenograft (PDX) of 3 EGFR Ex20Ins (V769_D770InsASV, M766_A767insASV, H773_V774insNPH) were used for in vivo experiments. Xenografts were treated by oral gavage with vehicle, erlotinib (50 mg/kg/day) or afatinib (20 mg/kg/day), osimertinib metabolite AZ5104 (50 mg/kg/day) and osimertinib (25 mg/kg/day) and assessed for tumor growth inhibition (TGI). Immunoblotting was performed for EGFR and relevant signaling pathways. A pt from whom the V769_D770InsASV Ex20ins PDX was derived was treated on a UC Davis IRB approved protocol with osimertinib at 160 mg PO once-daily (QD). Results: At completion of treatment, QD administration of osimertinib or AZ5104 induced significant TGI in xenografts across the 4 EGFR Ex20ins tested (range 60-95% TGI, p < 0.001 compared to control for all models) that was superior to either afatinib or erlotinib. Robust decrease in p-EGFR, p-ERK, p-Akt, p-Stat3 was observed with osimertinib treatment. The patient corresponding to the V769_D770InsASV Ex20ins PDX treated with osimertinib exhibited clinical improvement and tumor shrinkage; unfortunately he was found to have interstitial pneumonitis that necessitated drug discontinuation. Conclusions: Osimertinib at clinically representative doses has in vivo activity across multiple EGFR Ex20ins that comprising the most common Ex20ins detected in patients (~50% prevalence); metabolite AZ5104 may contribute to efficacy. Tumor shrinkage was observed in a patient with lung cancer harboring an Ex20ins treated for a limited time with osimertinib. Based on this in vivo xenograft and pt data, osimertinib warrants further study in pts with EGFR Ex20ins NSCLC.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | - Daniel Vang
- University of California Davis Comprehensive Cancer Center, Sacramento, CA
| | - Rebekah Tsai
- University of California Davis Comprehensive Cancer Center, Sacramento, CA
| | | | | | - David R. Gandara
- University of California Davis Comprehensive Cancer Center, Sacramento, CA
| | - Philip C. Mack
- University of California Davis Comprehensive Cancer Center, Sacramento, CA
| | | |
Collapse
|
50
|
Dąbrowska-Bender M, Milewska M, Gołąbek A, Duda-Zalewska A, Staniszewska A. The Impact of Ischemic Cerebral Stroke on the Quality of Life of Patients Based on Clinical, Social, and Psychoemotional Factors. J Stroke Cerebrovasc Dis 2017; 26:101-107. [DOI: 10.1016/j.jstrokecerebrovasdis.2016.08.036] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2016] [Revised: 08/02/2016] [Accepted: 08/23/2016] [Indexed: 10/20/2022] Open
|